Parental lifespan	1	5	0.2
Response to paliperidone in schizophrenia (Multivariate)	1	26	0.0384615384615385
Visceral adipose tissue	2	5	0.4
Delta-5 desaturase activity	2	8	0.25
Chickenpox	2	32	0.0625
Immunoglobulin light chain (AL) amyloidosis (serum Ig light chain only lambda based profile)	1	1	1
Eosinophil percentage of white cells	24	190	0.126315789473684
Multiple system atrophy (pathologically confirmed)	1	5	0.2
Bone mineral density (paediatric, skull)	5	19	0.263157894736842
Hormone measurements	1	7	0.142857142857143
Urate levels in overweight individuals	7	43	0.162790697674419
Multiple sclerosis (severity)	3	12	0.25
Risky sexual behaviors (alcohol dependence interaction)	1	8	0.125
Optic disc area	13	65	0.2
Diabetes in response to antihypertensive drug treatment (treatment strategy interaction)	2	3	0.666666666666667
Systemic lupus erythematosus	88	402	0.218905472636816
Multiple sclerosis	79	313	0.252396166134185
Serum dimethylarginine levels (asymmetric/symetric ratio)	3	24	0.125
Congenital heart disease (maternal effect)	1	20	0.05
Longevity	6	52	0.115384615384615
QRS duration in Tripanosoma cruzi seropositivity	3	38	0.0789473684210526
Reticulocyte fraction of red cells	42	203	0.206896551724138
Response to hepatitis B vaccine	7	20	0.35
Visceral adipose tissue/subcutaneous adipose tissue ratio adjusted for BMI	1	4	0.25
Itch intensity from mosquito bite	7	98	0.0714285714285714
Sexual dimorphism in anthropometric traits	1	10	0.1
Executive inhibition (Stroop WIT and CIT) in attention deficit hyperactivity disorder	1	1	1
Cognitive ability	21	69	0.304347826086957
Cerebrospinal AB1-42 levels in Alzheimer's disease dementia	1	2	0.5
Renal function-related traits (BUN)	2	15	0.133333333333333
Lp (a) levels	2	5	0.4
Triglyceride levels in medium VLDL	1	19	0.0526315789473684
Vitamin D insufficiency	1	3	0.333333333333333
Lung adenocarcinoma	12	92	0.130434782608696
Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive)	1	4	0.25
Body mass index (change over time) in chronic obstructive pulmonary disease	1	6	0.166666666666667
Bladder cancer (smoking interaction)	1	5	0.2
Body mass index in asthmatics	3	6	0.5
Monocyte percentage of white cells	33	224	0.147321428571429
Waist-to-hip circumference ratio (recreational physical activity interaction)	1	2	0.5
Insulin levels	1	2	0.5
Economic and political preferences	2	17	0.117647058823529
Red blood cell traits	19	84	0.226190476190476
Type 1 diabetes nephropathy	4	11	0.363636363636364
Fear of pain	1	4	0.25
Alcohol consumption	5	44	0.113636363636364
QRS complex (12-leadsum)	4	21	0.19047619047619
Elevated serum prostate-specific antigen levels in healthy men	1	2	0.5
Response to platinum-based chemotherapy (carboplatin)	2	18	0.111111111111111
Cocaine dependence	2	15	0.133333333333333
Moyamoya disease	7	36	0.194444444444444
Adverse response to chemotherapy (neutropenia/leucopenia) (cyclophosphamide)	1	3	0.333333333333333
Cervical cancer	4	27	0.148148148148148
Glaucoma	2	13	0.153846153846154
Total cholesterol change in response to fenofibrate in statin-treated type 2 diabetes	3	35	0.0857142857142857
Parental extreme longevity (95 years and older)	13	70	0.185714285714286
Benign prostatic hyperplasia and/or lower urinary tract symptoms	1	1	1
Reticulocyte count	36	199	0.180904522613065
Psoriasis vulgaris	9	39	0.230769230769231
Aging (time to death)	1	3	0.333333333333333
World class endurance athleticism	1	3	0.333333333333333
Venlafaxine response in generalised anxiety disorder (responders vs non-responders after 24 weeks)	1	5	0.2
Mean corpuscular hemoglobin concentration	24	122	0.19672131147541
Pursuit maintenance gain	10	79	0.126582278481013
Sudden cardiac arrest	9	50	0.18
Heart rate variability traits (pvRSA/HF)	5	12	0.416666666666667
Neurofibrillary tangles or cerebral amyloid angiopathy (pleiotropy)	1	2	0.5
Periodontitis (CDC/AAP)	1	28	0.0357142857142857
Thrombin-activatable fibrinolysis inhibitor activation peptide	1	11	0.0909090909090909
Urinary 1,3-butadiene metabolite levels in smokers	2	4	0.5
Response to methotrexate in juvenile idiopathic arthritis	1	18	0.0555555555555556
Non-alcoholic fatty liver disease histology (lobular)	4	13	0.307692307692308
Stearic acid (18:0) levels	3	11	0.272727272727273
Verbal memory performance (residualized delayed recall change)	2	4	0.5
Psychosis in Alzheimer's disease	3	8	0.375
Waist circumference adjusted for body mass index	100	441	0.226757369614512
Low vWF levels	2	10	0.2
Response to methotrexate in rheumatoid arthritis	1	2	0.5
Electrocardiographic conduction measures	3	12	0.25
Bone mineral accretion in asthma (oral corticosteroid dose interaction)	3	9	0.333333333333333
Infantile hypertrophic pyloric stenosis	5	9	0.555555555555556
Common carotid intima-media thickness in HIV infection	2	12	0.166666666666667
Growth-regulated protein alpha levels	4	26	0.153846153846154
Dietary macronutrient intake	5	10	0.5
Breast size	10	54	0.185185185185185
Asymmetrical dimethylarginine levels	2	22	0.0909090909090909
Mild influenza (H1N1) infection	2	35	0.0571428571428571
Acute lymphoblastic leukemia (B-cell precursor)	1	6	0.166666666666667
Lung cancer	27	182	0.148351648351648
Body mass index (ever vs never smoking interaction)	2	3	0.666666666666667
Sum neutrophil eosinophil counts	25	148	0.168918918918919
Left ventricle wall thickness	3	21	0.142857142857143
Obesity-related traits	185	957	0.193312434691745
Biomedical quantitative traits	1	8	0.125
Urinary metabolite concentrations in chronic kidney disease	2	9	0.222222222222222
Blood pressure measurement (high sodium intervention)	2	11	0.181818181818182
Hepatocellular carcinoma in hepatitis B infection	2	4	0.5
Exploratory eye movement dysfunction in schizophrenia (number of eye fixations)	3	19	0.157894736842105
Inflammatory bowel disease	122	487	0.250513347022587
Crohn's disease and psoriasis	1	4	0.25
Response to paliperidone in schizophrenia (CGI-S score)	4	28	0.142857142857143
Metabolite levels  (X-11787)	4	29	0.137931034482759
Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer	3	13	0.230769230769231
Tumor necrosis factor beta levels	2	11	0.181818181818182
Response to tamoxifen in breast cancer	1	1	1
Anterior cruciate ligament rupture	1	3	0.333333333333333
Alzheimer's disease	19	79	0.240506329113924
Iris characteristics	1	7	0.142857142857143
Lipoprotein-associated phospholipase A2 activity and mass	6	21	0.285714285714286
Major coronary event in darapladib-treated cardiovascular disease (time to event)	1	2	0.5
Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1)	8	57	0.140350877192982
Axial length	3	22	0.136363636363636
Migraine	31	146	0.212328767123288
Nonsyndromic cleft lip with cleft palate	10	56	0.178571428571429
Eating disorder in bipolar disorder	2	5	0.4
Suicide ideation score in major depressive disorder	1	3	0.333333333333333
Serum metabolite ratios in chronic kidney disease	86	259	0.332046332046332
Apolipoprotein A-IV levels	1	4	0.25
Plasma cystastin c levels in acute coronary syndrome	1	2	0.5
Kidney stones	2	5	0.4
Body mass index (joint analysis main effects and smoking interaction)	25	140	0.178571428571429
Acute lymphoblastic leukemia in childhood (B cell precursor)	1	2	0.5
Hippocampal sclerosis of aging	1	1	1
Alcoholic chronic pancreatitis	20	137	0.145985401459854
Multiple sclerosis (age of onset)	1	8	0.125
Hepatitis B virus-related hepatocellular carcinoma	1	2	0.5
Parental longevity (combined parental age at death)	5	51	0.0980392156862745
Crohn's disease-related phenotypes	2	7	0.285714285714286
Hair greying	1	8	0.125
Type 2 diabetes	178	766	0.232375979112272
TRAIL levels	4	58	0.0689655172413793
Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin)	1	7	0.142857142857143
Lean body mass	1	8	0.125
Heart rate response to beta blockers	1	2	0.5
Local histogram emphysema pattern	4	25	0.16
Body mass index  (smoking years interaction)	1	3	0.333333333333333
Formal thought disorder in schizophrenia	1	5	0.2
Verbal declarative memory	13	43	0.302325581395349
Inflammatory bowel disease (early onset)	1	4	0.25
Pulse pressure	32	159	0.20125786163522
HIV-associated neurocognitive disorder (mild neurocognitive disorder or asymptomatic neurocognitive impairment)	2	4	0.5
Capecitabine sensitivity	3	22	0.136363636363636
Alcoholism (alcohol dependence factor score)	1	6	0.166666666666667
Platelet-derived growth factor BB levels	2	38	0.0526315789473684
Kawasaki disease	1	20	0.05
Hip geometry	5	16	0.3125
Sitting height ratio	10	44	0.227272727272727
Dysphagia	3	19	0.157894736842105
Beta-2 microglubulin plasma levels	3	7	0.428571428571429
Facial morphology (factor 19)	2	32	0.0625
Conduct disorder	2	12	0.166666666666667
Response to cytadine analogues (cytosine arabinoside)	3	22	0.136363636363636
HIV-1 susceptibility	4	25	0.16
Narcolepsy with cataplexy	5	8	0.625
Glycerophospholipid levels	11	38	0.289473684210526
Response to cyclophosphamide in systemic lupus erythematosus with lupus nephritis	1	14	0.0714285714285714
Progressive supranuclear palsy	2	11	0.181818181818182
Scalp hair shape	3	9	0.333333333333333
Esophageal adenocarcinoma	2	13	0.153846153846154
Neurofibrillary tangles	6	22	0.272727272727273
Prudent dietary pattern	3	42	0.0714285714285714
Plasma lactate levels	4	4	1
Fibroblast growth factor basic levels	2	28	0.0714285714285714
Facial morphology (factor 5, width of mouth relative to central midface)	3	16	0.1875
QT interval in Tripanosoma cruzi seropositivity	1	14	0.0714285714285714
Total cholesterol levels in HDL	1	8	0.125
Midgestational circulating levels of PBDEs (fetal genetic effect)	2	11	0.181818181818182
Ossification of the posterior longitudinal ligament of the spine	2	8	0.25
Low white blood cell count (conditioned on rs2814778)	2	16	0.125
Posterior cortical atrophy and Alzheimer's disease	4	18	0.222222222222222
Juvenile idiopathic arthritis (oligoarticular or rheumatoid factor-negative polyarticular)	5	31	0.161290322580645
Educational attainment (college completion)	7	34	0.205882352941176
Gut microbiome composition (summer)	12	35	0.342857142857143
Response to abacavir-containing treatment in HIV-1 infection (virologic failure)	1	27	0.037037037037037
Bone mineral density (spine) and age at menarche	1	9	0.111111111111111
Perceived unattractiveness to mosquitoes	5	45	0.111111111111111
Fat distribution (HIV)	3	17	0.176470588235294
Telomere length	10	38	0.263157894736842
Celiac disease	26	113	0.230088495575221
Overall survival in osteosarcoma	2	9	0.222222222222222
Methadone dose in opioid dependence	3	37	0.0810810810810811
Blood pressure traits (multi-trait analysis)	5	30	0.166666666666667
Immunoglobulin G index levels in multiple sclerosis	1	5	0.2
Inattentive symptoms	4	15	0.266666666666667
circulating leptin levels adjusted for BMI	3	9	0.333333333333333
Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy)	4	11	0.363636363636364
Psychosis proneness (hypomanic personality scale)	1	6	0.166666666666667
Hypertriglyceridemia	9	32	0.28125
Alzheimer's disease (APOE e4 interaction)	1	5	0.2
Height	162	855	0.189473684210526
Low high density lipoprotein cholesterol levels	2	11	0.181818181818182
Amyotrophic lateral sclerosis (sporadic)	15	99	0.151515151515152
F-cell distribution	15	51	0.294117647058824
Sj√∂gren's syndrome	7	51	0.137254901960784
Age-related diseases and mortality	3	14	0.214285714285714
Extraversion	1	5	0.2
Borderline personality disorder	2	24	0.0833333333333333
Vertical cup-disc ratio	17	73	0.232876712328767
Cutaneous psoriasis	3	10	0.3
Glaucoma (primary angle closure)	10	22	0.454545454545455
IgA nephropathy	12	63	0.19047619047619
Response to hepatitis C treatment	3	19	0.157894736842105
Nicotine dependence	3	21	0.142857142857143
Pneumonia	3	59	0.0508474576271186
Endometriosis	19	114	0.166666666666667
Anxiety disorder	6	16	0.375
Gait speed in old age	6	19	0.315789473684211
Total cholesterol levels	30	99	0.303030303030303
Clozapine-induced cytotoxicity	3	18	0.166666666666667
Vaccenic acid (18:1n-7) levels	4	4	1
Peak insulin response	2	10	0.2
Gastric adenocarcinoma (histologically verified)	1	3	0.333333333333333
Bone mineral density (hip)	6	41	0.146341463414634
Sulfasalazine-induced agranulocytosis	1	30	0.0333333333333333
Plasma t-tau levels	1	4	0.25
Bipolar disorder (inflammation and infection response interaction)	2	5	0.4
Hepatitis C induced liver cirrhosis	1	5	0.2
Milk allergy (parent-of-origin effect)	1	2	0.5
Gait variability	1	3	0.333333333333333
Hematological and biochemical traits	6	29	0.206896551724138
Sphingolipid levels	7	22	0.318181818181818
Gut microbiota (beta diversity)	1	15	0.0666666666666667
Systemic sclerosis	15	64	0.234375
Residual cognition	1	9	0.111111111111111
Stroke (ischemic)	4	10	0.4
Mean forced vital capacity from 2 exams	2	2	1
Periodontitis	1	6	0.166666666666667
Myopia	15	55	0.272727272727273
Obesity and osteoporosis	1	2	0.5
Temperament (bipolar disorder)	2	13	0.153846153846154
Immunoglobulin light chain (AL) amyloidosis (kidney involvement)	1	1	1
Narcolepsy	6	17	0.352941176470588
Eosinophil percentage of granulocytes	26	179	0.145251396648045
Self-employment	1	2	0.5
Fasting plasma glucose	6	47	0.127659574468085
Recurrent major depressive disorder	2	23	0.0869565217391304
Allergic disease (asthma, hay fever or eczema)	21	136	0.154411764705882
Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction)	49	253	0.193675889328063
Adverse response to lamotrigine and phenytoin	1	12	0.0833333333333333
Adverse response to chemotherapy in breast cancer (alopecia)	1	3	0.333333333333333
Fibrinogen	7	39	0.179487179487179
Epilepsy	1	10	0.1
Endometrial cancer	5	23	0.217391304347826
Schizophrenia, schizoaffective disorder or bipolar disorder	1	5	0.2
Illicit drug use	2	10	0.2
Age-related hearing impairment (SNP x SNP interaction)	20	98	0.204081632653061
Life satisfaction	7	28	0.25
Nose size	1	23	0.0434782608695652
Cutaneous nevi	1	5	0.2
Abdominal aortic aneurysm	4	16	0.25
Metabolite levels	21	104	0.201923076923077
Eye color	2	19	0.105263157894737
Lymphocyte percentage of white cells	15	140	0.107142857142857
Antipsychotic drug-induced QTc interval prolongation	1	3	0.333333333333333
Acenocoumarol maintenance dosage	1	4	0.25
Palmitic acid (16:0) levels	5	12	0.416666666666667
Eosinophilic esophagitis (pediatric)	3	14	0.214285714285714
Smooth-surface caries	11	42	0.261904761904762
Crohn's disease and sarcoidosis (combined)	1	1	1
Cancer	33	170	0.194117647058824
Pit-and-Fissure caries	4	22	0.181818181818182
Glucagon levels in response to oral glucose tolerance test (fasting)	1	4	0.25
Carotid plaque burden (smoking interaction)	1	4	0.25
Mortality in heart failure	2	13	0.153846153846154
Mean corpuscular hemoglobin	60	352	0.170454545454545
Ulcerative colitis	98	386	0.253886010362694
Sense of smell	6	22	0.272727272727273
Deep ovarian and/or rectovaginal disease with dense adhesions	1	10	0.1
Total ventricular volume	1	8	0.125
Alcohol and nicotine co-dependence	1	10	0.1
Immune reponse to smallpox (secreted IL-10)	2	6	0.333333333333333
Daytime sleep phenotypes	7	92	0.0760869565217391
TB-LM or TBLH-BMD (pleiotropy)	5	12	0.416666666666667
Incremental insulin	2	3	0.666666666666667
Economic and political preferences (feminism/equality)	1	12	0.0833333333333333
Coronary heart disease (SNP X SNP interaction)	2	10	0.2
Kashin-Beck disease	1	1	1
Waist circumference	15	138	0.108695652173913
End-stage coagulation	3	23	0.130434782608696
Visceral adipose tissue/subcutaneous adipose tissue ratio	13	49	0.26530612244898
Renal function-related traits (eGRFcrea)	4	10	0.4
Prion diseases	3	11	0.272727272727273
Morbidity-free survival	1	5	0.2
Small vessel stroke	3	9	0.333333333333333
Rheumatoid arthritis (ACPA-negative)	1	8	0.125
Urinary uromodulin levels	2	5	0.4
Aortic valve stenosis	1	5	0.2
Milk allergy	1	5	0.2
Metabolite levels (MHPG)	2	20	0.1
Aggressive periodontitis (sex interaction)	1	1	1
Plasma estrone conjugates levels in resected early stage estrogen-receptor positive breast cancer	1	2	0.5
Antipsychotic drug-induced QTc interval change in schizophrenia	7	34	0.205882352941176
Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction)	6	45	0.133333333333333
Bipolar disorder or major depressive disorder (combined)	1	9	0.111111111111111
Serum uric acid levels	5	23	0.217391304347826
Social autistic-like traits	1	6	0.166666666666667
Estradiol plasma levels (breast cancer)	8	18	0.444444444444444
Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid)	3	22	0.136363636363636
Antibody level in response to infection	2	7	0.285714285714286
Binge eating behaviour in bipolar disorder	1	6	0.166666666666667
Survival in pancreatic cancer	4	61	0.0655737704918033
White matter hyperintensities in ischemic stroke	1	8	0.125
Waist-to-hip ratio adjusted for BMI in non-smokers	6	46	0.130434782608696
Diffuse cutaneous systemic sclerosis	3	7	0.428571428571429
Epstein-Barr virus copy number in lymphoblastoid cell lines	8	42	0.19047619047619
Subjective response to lithium treatment	2	4	0.5
Breastfeeding duration	3	9	0.333333333333333
Corneal astigmatism	4	30	0.133333333333333
Ischemic stroke	3	29	0.103448275862069
Facial morphology (factor 14, intercanthal width)	3	21	0.142857142857143
Neuroticism	55	326	0.168711656441718
GIP levels in response to oral glucose tolerance test (120 minutes)	3	12	0.25
RR interval (tricyclic/tetracyclic antidepressant use interaction)	2	3	0.666666666666667
Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour)	21	116	0.181034482758621
Activated partial thromboplastin time	2	12	0.166666666666667
Amino acid levels	2	9	0.222222222222222
Behcet's disease	4	19	0.210526315789474
Nicotine use	1	6	0.166666666666667
Response to acetaminophen (hepatotoxicity)	1	5	0.2
Survival in rectal cancer	3	18	0.166666666666667
Periodontal microbiota	3	16	0.1875
Chronic obstructive pulmonary disease (severe)	1	6	0.166666666666667
Periodontitis (PAL4Q3)	4	18	0.222222222222222
Response to clopidogrel therapy	1	1	1
Incident coronary heart disease	1	2	0.5
QRS interval (sulfonylurea treatment interaction)	1	18	0.0555555555555556
Neonatal lupus	1	5	0.2
Midgestational circulating levels of PCBs (fetal genetic effect)	1	11	0.0909090909090909
Caffeine metabolism (plasma 1,3,7-trimethylxanthine (caffeine) level)	1	11	0.0909090909090909
Coffee consumption (cups per day)	3	9	0.333333333333333
Matrix metalloproteinase levels	1	4	0.25
Venous thromboembolism (SNP x SNP interaction)	14	74	0.189189189189189
Waist circumference adjusted for BMI (adjusted for smoking behaviour)	33	140	0.235714285714286
Measles	3	32	0.09375
Idiopathic membranous nephropathy	7	21	0.333333333333333
Interleukin-10 levels	3	34	0.0882352941176471
Bipolar disorder and eating disorder	2	10	0.2
Epstein Barr virus nuclear antigen 1 IgG levels or multiple sclerosis	1	4	0.25
Vitamin D levels	3	39	0.0769230769230769
Visceral adipose tissue adjusted for BMI	16	51	0.313725490196078
Lymphoma	5	13	0.384615384615385
Intelligence	23	93	0.247311827956989
Metabolite levels (HVA-5-HIAA Factor score)	1	12	0.0833333333333333
Exploratory eye movement dysfunction in schizophrenia (total eye scanning length)	2	8	0.25
Monocyte chemoattractant protein-3 levels	4	14	0.285714285714286
Hematocrit	34	154	0.220779220779221
Ulcerative colitis or Crohn's disease	1	2	0.5
Eosinophil counts	32	208	0.153846153846154
Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer	4	12	0.333333333333333
DNA methylation (parent-of-origin)	1	7	0.142857142857143
Sleep duration (oversleepers vs undersleepers)	1	2	0.5
Two-hour glucose challenge	1	5	0.2
Body mass index in physically inactive individuals	11	45	0.244444444444444
Morning vs. evening chronotype	14	102	0.137254901960784
Body mass index (adult)	1	32	0.03125
Macrophage Migration Inhibitory Factor levels	1	26	0.0384615384615385
Lung function (forced expiratory flow during mid-portion (25% and 75%) of forced vital capacity)	4	12	0.333333333333333
Caffeine consumption	1	10	0.1
Blood protein levels	167	590	0.283050847457627
Plasma kynurenine levels in major depressive disorder	2	7	0.285714285714286
Depressive episodes in bipolar disorder	1	7	0.142857142857143
Adverse response to chemotherapy (neutropenia/leucopenia) (all anthracycline-based drugs)	1	6	0.166666666666667
Inhibitory control	2	9	0.222222222222222
Restless legs syndrome	2	32	0.0625
Depression and alcohol dependence	2	8	0.25
Alcohol dependence symptom count	5	23	0.217391304347826
Urinary albumin-to-creatinine ratio in non-diabetics	4	10	0.4
Major depressive disorder (stressful life events interaction)	1	2	0.5
Laryngeal squamous cell carcinoma	3	6	0.5
Oral cavity cancer	1	9	0.111111111111111
Renal sinus fat	2	8	0.25
Sclerosing cholangitis and ulcerative colitis (combined)	1	2	0.5
Polychlorinated biphenyl levels	6	57	0.105263157894737
Eosinophilic esophagitis	9	23	0.391304347826087
Tragus size	1	1	1
Heart rate variability traits	1	4	0.25
Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction)	27	135	0.2
Cleft lip	1	2	0.5
QT interval	36	218	0.165137614678899
Iron status biomarkers (total iron binding capacity)	7	34	0.205882352941176
Schizophrenia (inflammation and infection response interaction)	1	4	0.25
Graves' disease	13	35	0.371428571428571
Idiopathic dilated cardiomyopathy	6	42	0.142857142857143
Estrogen receptor status in HER2 negative breast cancer	1	1	1
Adult asthma	2	24	0.0833333333333333
Clinically amyopathic dermatomyositis	1	1	1
Immune reponse to smallpox (secreted TNF-alpha)	1	6	0.166666666666667
Dementia and core Alzheimer's disease neuropathologic changes	4	27	0.148148148148148
Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface)	1	16	0.0625
Inguinal hernia	2	4	0.5
Spontaneous preterm birth (preterm delivery)	1	2	0.5
C-reactive protein (red blood cell fatty acid level interaction)	1	2	0.5
Anti-saccade response	3	39	0.0769230769230769
Insulin disposition index	1	5	0.2
antipsychotic drug dosage in schizophrenia or schizoaffective disorder	3	21	0.142857142857143
Ovarian disease with few adhesions	1	4	0.25
Diabetic retinopathy	3	28	0.107142857142857
Cerebral amyloid deposition (PET imaging)	1	17	0.0588235294117647
Trans fatty acid levels	19	131	0.145038167938931
Alzheimer's disease (age of onset)	2	13	0.153846153846154
Political ideology	4	19	0.210526315789474
Response to TNF-alpha inhibitors in rheumatoid arthritis	2	8	0.25
Corneal curvature	6	18	0.333333333333333
Intelligence (childhood)	1	6	0.166666666666667
Delta-5 desaturase activity response to n3-polyunsaturated fat supplement	4	6	0.666666666666667
Lung cancer in ever smokers	12	110	0.109090909090909
Pediatric bone mineral content (spine)	4	12	0.333333333333333
Left atrial antero-posterior diameter	5	16	0.3125
Hepatocellular carcinoma	3	8	0.375
Mosaic loss of chromosome Y	1	1	1
Cisplatin-induced ototoxicity	3	20	0.15
Clostridium difficile infection in multiple myeloma	19	54	0.351851851851852
Age-related macular degeneration (geographic atrophy)	2	9	0.222222222222222
Neurocognitive impairment in HIV-1 infection (dichotomous)	1	9	0.111111111111111
QT interval (drug interaction)	3	17	0.176470588235294
Breast cancer (prognosis)	3	5	0.6
Blood trace element (Zn levels)	2	11	0.181818181818182
Phospholipid levels in large HDL	1	12	0.0833333333333333
Urgency urinary incontinence	1	6	0.166666666666667
Economic and political preferences (immigration/crime)	2	15	0.133333333333333
Colorectal cancer (SNP x SNP interaction)	2	14	0.142857142857143
Lupus nephritis in systemic lupus erythematosus	2	17	0.117647058823529
Response to zileuton treatment in asthma (FEV1 change interaction)	5	21	0.238095238095238
Drug-induced Stevens-Johnson syndrome or toxic epidermal necrolysis (SJS/TEN)	1	10	0.1
&beta;2-Glycoprotein I (&beta;2-GPI) plasma levels	3	9	0.333333333333333
Urinary albumin-to-creatinine ratio	2	15	0.133333333333333
JT interval (sulfonylurea treatment interaction)	5	14	0.357142857142857
Spherical equivalent (joint analysis main effects and education interaction)	10	48	0.208333333333333
Barrett's esophagus	3	17	0.176470588235294
Forced expiratory volume in 1 second (environmental tobacco smoke interaction)	1	3	0.333333333333333
Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs)	2	12	0.166666666666667
Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin)	3	9	0.333333333333333
Male infertility	2	5	0.4
Energy expenditure (24h)	3	9	0.333333333333333
Nose morphology	1	8	0.125
Response to paliperidone in schizophrenia (positive Marder score)	6	60	0.1
Testicular germ cell cancer	1	6	0.166666666666667
Orofacial clefts	13	82	0.158536585365854
Major mood disorders	1	1	1
Alzheimer disease and age of onset	12	203	0.0591133004926108
Glycemic traits	2	11	0.181818181818182
Response to serotonin reuptake inhibitors in major depressive disorder	3	20	0.15
Insulin levels adjusted for BMI	2	4	0.5
Calcium levels	18	42	0.428571428571429
IgG glycosylation	135	699	0.1931330472103
Response to radiotherapy in prostate cancer (overall toxicity)	1	16	0.0625
Red blood cell count	48	240	0.2
HIV-1 control	5	50	0.1
S-phenylmercapturic acid levels in smokers	1	2	0.5
C-peptide levels in type I diabetes	1	4	0.25
Neovascular age-related macular degeneration	1	4	0.25
Leishmaniasis (visceral)	1	1	1
Corrected insulin response adjusted for insulin sensitivity index	2	6	0.333333333333333
Huntington's disease progression	2	20	0.1
Temporomandibular joint disorder	1	6	0.166666666666667
Progranulin levels	2	4	0.5
Coenzyme Q10 levels	2	25	0.08
Childhood and early adolescence aggressive behavior	1	6	0.166666666666667
Sleep duration	4	34	0.117647058823529
Inflammatory skin disease	15	88	0.170454545454545
Small cell lung carcinoma	4	50	0.08
Cerebrospinal fluid AB1-42 levels	3	35	0.0857142857142857
Urinary tract infection frequency	7	61	0.114754098360656
Response to gemcitabine in pancreatic cancer	2	5	0.4
Gut microbiota (functional units)	6	56	0.107142857142857
Frontotemporal dementia	15	35	0.428571428571429
Aging (time to event)	3	8	0.375
Pediatric autoimmune diseases	9	46	0.195652173913043
LDL cholesterol	44	238	0.184873949579832
Schizophrenia	172	1130	0.152212389380531
Atrioventricular conduction	1	5	0.2
Red cell distribution width	30	206	0.145631067961165
Electroencephalogram traits	1	27	0.037037037037037
Multiple myeloma	8	40	0.2
Osteoarthritis of the hip (with total joint replacement)	2	6	0.333333333333333
Tumor biomarkers	3	11	0.272727272727273
Chronic lymphocytic leukemia	19	126	0.150793650793651
Risky sexual behaviors in alcohol dependence	1	4	0.25
Chronic kidney disease	3	46	0.0652173913043478
Response to fenofibrate	1	10	0.1
Cutaneous malignant melanoma	1	16	0.0625
Response to inhaled corticosteroid treatment in asthma (change in FEV1)	4	21	0.19047619047619
Hip minimal joint space width	2	9	0.222222222222222
Serum alkaline phosphatase levels	1	4	0.25
Pain	3	4	0.75
Blood metabolite ratios	13	54	0.240740740740741
Myocardial infarction in hypertension (calcium channel blocker interaction)	1	1	1
Skin pigmentation	9	47	0.191489361702128
Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid)	2	17	0.117647058823529
3-hydroxypropylmercapturic acid levels in smokers	17	246	0.0691056910569106
Cancer (pleiotropy)	4	26	0.153846153846154
Gastric cancer	3	11	0.272727272727273
Bacteremia	2	12	0.166666666666667
Response to antidepressants	3	9	0.333333333333333
Methotrexate phramacokinetics (acute lymphoblastic leukemia)	3	21	0.142857142857143
Gaucher disease severity	1	3	0.333333333333333
Odorant perception (isobutyraldehyde)	1	1	1
Coronary heart disease	24	108	0.222222222222222
Chronic mucus hypersecretion	5	5	1
Attention deficit hyperactivity disorder (hyperactivity-impulsivity symptoms)	4	25	0.16
Non-albumin protein levels	1	5	0.2
IgG galactosylation phenotypes (multivariate analysis)	1	9	0.111111111111111
Serum metabolite levels	5	19	0.263157894736842
C-reactive protein and white blood cell count	2	9	0.222222222222222
Rubella	1	38	0.0263157894736842
Very long-chain saturated fatty acid levels (fatty acid 22:0)	2	11	0.181818181818182
Tetralogy of Fallot	3	6	0.5
Exfoliation glaucoma or exfoliation syndrome	2	2	1
Clozapine-induced agranulocytosis	4	28	0.142857142857143
Depressive symptoms (MTAG)	17	64	0.265625
Anthropometric traits	2	13	0.153846153846154
Age at smoking initiation in chronic obstructive pulmonary disease	5	21	0.238095238095238
Glucocorticoid-induced osteonecrosis	1	10	0.1
Problematic alcohol use in trauma-exposed individuals	1	5	0.2
Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid)	3	24	0.125
C-reactive protein levels or LDL-cholesterol levels (pleiotropy)	5	21	0.238095238095238
Amyotrophic lateral sclerosis in C9orf72 mutation negative individuals	1	4	0.25
Lung function (forced vital capacity)	1	9	0.111111111111111
Multiple myeloma and monoclonal gammopathy	2	9	0.222222222222222
Platelet thrombus formation	1	6	0.166666666666667
Primary sclerosing cholangitis	11	32	0.34375
Optic nerve measurement (disc area)	1	7	0.142857142857143
Osteoarthritis	2	8	0.25
Systemic juvenile idiopathic arthritis	5	25	0.2
Interleukin-9 levels	3	25	0.12
Interleukin-8 levels	2	18	0.111111111111111
Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel)	3	7	0.428571428571429
Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab)	2	13	0.153846153846154
Response to antipsychotic treatment	14	57	0.245614035087719
Gout	13	66	0.196969696969697
Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid)	3	20	0.15
Waist circumference and related phenotypes	1	4	0.25
Parkinson's disease (motor and cognition)	1	5	0.2
Cannabis use	1	6	0.166666666666667
Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes	7	84	0.0833333333333333
Metabolite levels (lipoprotein measures)	6	31	0.193548387096774
Gastritis	1	7	0.142857142857143
Tonsillectomy	23	234	0.0982905982905983
Basophil percentage of granulocytes	7	58	0.120689655172414
Clozapine-induced agranulocytosis/granulocytopenia in treatment-resistant schizophrenia	1	12	0.0833333333333333
Warfarin maintenance dose	6	29	0.206896551724138
Neurocognitive impairment in HIV-1 infection (continuous)	1	6	0.166666666666667
Epithelial ovarian cancer	5	48	0.104166666666667
Serum prostate-specific antigen levels	2	7	0.285714285714286
Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU)	1	8	0.125
Chronic obstructive pulmonary disease	10	53	0.188679245283019
Migraine without aura	4	41	0.0975609756097561
Non-word repetition	1	5	0.2
Corneal structure	5	31	0.161290322580645
Cerebrospinal fluid t-tau levels	2	7	0.285714285714286
Personality traits in bipolar disorder	4	7	0.571428571428571
Mononucleosis	3	44	0.0681818181818182
Uveal melanoma	1	2	0.5
Influenza A (H1N1) infection	2	14	0.142857142857143
Sunburns	1	4	0.25
Stroke	2	37	0.0540540540540541
Spontaneous dizygotic twinning	1	3	0.333333333333333
ADAMTS13 activity	1	4	0.25
Iris color (b* coordinate)	1	7	0.142857142857143
Area under the curve of insulin levels	1	2	0.5
Follicule stimulating hormone	1	6	0.166666666666667
White blood cell types	2	20	0.1
Freckling	1	4	0.25
Hepatitis B	7	47	0.148936170212766
Serum alpha1-antitrypsin levels	1	3	0.333333333333333
Cardiac Troponin-T levels	5	18	0.277777777777778
Allergic rhinitis in non-asthmatics	1	7	0.142857142857143
Tanning	2	19	0.105263157894737
Night sleep phenotypes	14	193	0.0725388601036269
Age-related nuclear cataracts	1	15	0.0666666666666667
Bone erosion in rheumatoid arthritis	1	2	0.5
Neuroticism (MTAG)	7	37	0.189189189189189
Headache	4	28	0.142857142857143
Interleukin-18 levels	2	46	0.0434782608695652
Suicide attempts in depression or bipolar disorder	2	3	0.666666666666667
Coronary artery disease	165	747	0.220883534136546
Multiple sclerosis (OCB status)	5	12	0.416666666666667
PCA3 expression level	3	4	0.75
Alzheimer's disease (cognitive decline)	10	44	0.227272727272727
Lobe attachment (rater-scored or self-reported)	28	177	0.15819209039548
Hypertension (SNP x SNP interaction)	4	18	0.222222222222222
Lung function (FVC)	4	29	0.137931034482759
Advanced glycation end-product levels	3	7	0.428571428571429
Gut microbiome composition (summer and winter)	1	9	0.111111111111111
Soluble interleukin-2 receptor subunit alpha	1	7	0.142857142857143
Platelet count	67	383	0.174934725848564
Protein C levels	3	8	0.375
Uric acid levels	11	42	0.261904761904762
NT-proBNP levels in acute coronary syndrome	1	3	0.333333333333333
Parasitemia in Tripanosoma cruzi seropositivity	2	24	0.0833333333333333
Glioma (high-grade)	3	6	0.5
Delta-6 desaturase activity	4	9	0.444444444444444
Knee osteoarthritis	4	15	0.266666666666667
Cognitive test performance	5	14	0.357142857142857
Gut microbiome composition (winter)	4	33	0.121212121212121
Non-substance related behavioral disinhibition	1	4	0.25
Facial emotion recognition (angry faces)	1	4	0.25
Monobrow thickness	2	7	0.285714285714286
EGFR mutation-positive lung adenocarcinoma	1	6	0.166666666666667
Overweight status	1	3	0.333333333333333
Colorectal cancer	66	311	0.212218649517685
Glucose homeostasis traits	15	74	0.202702702702703
Sex hormone-binding globulin levels	10	38	0.263157894736842
Survival in microsatellite instability low/stable colorectal cancer	4	12	0.333333333333333
Immunoglobulin A	2	12	0.166666666666667
Liver fibrosis severity in HIV/hepatitis C co-infection	1	7	0.142857142857143
Late-onset Alzheimer's disease	3	123	0.024390243902439
Acute insulin response	3	10	0.3
Electrocardiographic traits	5	32	0.15625
Alopecia areata	10	44	0.227272727272727
Monokine induced by gamma interferon levels	3	35	0.0857142857142857
Pancreatic cancer	17	101	0.168316831683168
Pediatric areal bone mineral density (radius)	3	16	0.1875
Tooth agenesis (mandibular second premolars)	1	1	1
Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined)	1	10	0.1
Total body bone mineral density (age 0-15)	2	7	0.285714285714286
Information processing speed	7	31	0.225806451612903
Schizophrenia or bipolar disorder	3	12	0.25
C-reactive protein levels or triglyceride levels (pleiotropy)	4	21	0.19047619047619
Pediatric bone mineral content (femoral neck)	1	13	0.0769230769230769
Airway responsiveness in chronic obstructive pulmonary disease	2	26	0.0769230769230769
Erythrocyte cadmium concentration in never smokers	2	7	0.285714285714286
Erectile dysfunction and prostate cancer treatment	3	23	0.130434782608696
Left ventricular obstructive tract defect (inherited effect)	2	15	0.133333333333333
Type 1 diabetes and autoimmune thyroid diseases	5	11	0.454545454545455
Serous borderline ovarian cancer	2	10	0.2
Fasting blood glucose	11	50	0.22
Myopia (pathological)	19	82	0.231707317073171
Response to Vitamin E supplementation	2	8	0.25
Fibrinogen levels	19	112	0.169642857142857
High light scatter reticulocyte percentage of red cells	35	194	0.180412371134021
Angiotensin-converting enzyme inhibitor intolerance	3	33	0.0909090909090909
Hemoglobin concentration	22	132	0.166666666666667
Carotid atherosclerosis in HIV infection	2	7	0.285714285714286
Mosquito bite size	11	147	0.0748299319727891
Blood metabolite levels	52	249	0.208835341365462
Breast cancer	190	1074	0.176908752327747
Periodontitis (DPAL)	3	15	0.2
Autism	17	53	0.320754716981132
Suicide	1	3	0.333333333333333
Phospholipid levels (plasma)	7	25	0.28
Pursuit maintenance gain in psychotic disorders	1	11	0.0909090909090909
Response to methylphenidate treatment in attention-deficit/hyperactivity disorder (blood pressure)	1	7	0.142857142857143
Coronary artery calcification	10	56	0.178571428571429
Adiponectin levels in pregnancy	2	3	0.666666666666667
Cerebral amyloid deposition positivity (PET imaging)	1	1	1
Liver fibrosis in pediatric non-alcoholic fatty acid liver disease	1	5	0.2
Creutzfeldt-Jakob disease (sporadic)	1	2	0.5
Pharmacokinetics of antidepressant drugs in severe mental disorder (concentration dose ratio)	1	1	1
Conotruncal heart defects (maternal effects)	3	22	0.136363636363636
Chronic hepatitis B infection	10	27	0.37037037037037
Giant cell arteritis	1	5	0.2
Coronary artery calcified atherosclerotic plaque score in type 2 diabetes	6	53	0.113207547169811
Disturbances of the gamma-frequency band of electroencephalography measures in schizophrenia	1	3	0.333333333333333
Systolic blood pressure response to hydrochlorothiazide in hypertension	1	10	0.1
Mumps	6	54	0.111111111111111
Select biomarker traits	4	21	0.19047619047619
3-hydroxy-1-methylpropylmercapturic acid levels in smokers	27	239	0.112970711297071
Systemic lupus erythematosus and Systemic sclerosis	3	20	0.15
Atrial fibrillation	12	90	0.133333333333333
Congenital left-sided heart lesions	1	5	0.2
Anorexia nervosa	7	31	0.225806451612903
Dementia with Lewy bodies	1	4	0.25
Psychosis (atypical)	5	10	0.5
Cardiac hypertrophy	2	19	0.105263157894737
Insomnia	2	34	0.0588235294117647
Psychosis proneness (perceptual aberration scale)	1	3	0.333333333333333
Entorhinal cortical thickness (Alzheimer's disease interaction)	1	1	1
Ankle-brachial index	1	2	0.5
Self-reported allergy	7	35	0.2
Total bilirubin levels in HIV-1 infection	1	11	0.0909090909090909
Early childhood aggressive behavior	1	3	0.333333333333333
Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals	1	6	0.166666666666667
Bitter taste perception	1	3	0.333333333333333
Hepatitis	3	9	0.333333333333333
Ideal cardiovascular health (clinical and behavioural)	1	1	1
Coronary artery aneurysm in Kawasaki disease	4	22	0.181818181818182
Iron status biomarkers	10	53	0.188679245283019
Beard thickness	2	8	0.25
Nonalcoholic fatty liver disease	2	15	0.133333333333333
Glomerular filtration rate (creatinine)	22	119	0.184873949579832
Testosterone levels	1	7	0.142857142857143
Mean arterial pressure (alcohol consumption interaction)	2	9	0.222222222222222
Brain connectivity	2	12	0.166666666666667
Weight	4	34	0.117647058823529
Disc degeneration (lumbar)	4	37	0.108108108108108
Fractures (vertebral)	1	3	0.333333333333333
Nucleus accumbens volume in trauma-exposed individuals	1	4	0.25
Duloxetine response in major depressive disorder (% change in symptom score)	2	2	1
Insulin-like growth factors	1	8	0.125
Heart rate response to beta blockers (atenolol add-on therapy)	7	33	0.212121212121212
Aggressiveness in attention deficit hyperactivity disorder	1	32	0.03125
Chagas cardiomyopathy in Tripanosoma cruzi seropositivity	1	18	0.0555555555555556
Bipolar disorder or attention deficit hyperactivity disorder	2	15	0.133333333333333
Response to diuretic therapy	1	3	0.333333333333333
Adverse response to chemotherapy (neutropenia/leucopenia) (etoposide)	1	4	0.25
Vitamin B levels in ischemic stroke	1	8	0.125
Sporadic pituitary adenoma	1	4	0.25
Pharmacokinetics of antipsychotic drugs in severe mental disorder (concentration drug ratio)	3	3	1
Nephrotic syndrome (acquired)	2	2	1
Stem cell growth factor beta levels	1	53	0.0188679245283019
Thrombomodulin levels in ischemic stroke	2	7	0.285714285714286
Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined)	6	74	0.0810810810810811
Interleukin-12p70 levels	4	36	0.111111111111111
Interstitial lung disease	4	18	0.222222222222222
Alcoholism (heaviness of drinking)	2	8	0.25
Chronic obstructive pulmonary disease-related biomarkers	11	34	0.323529411764706
Lifetime average cigarettes per day in chronic obstructive pulmonary disease	3	11	0.272727272727273
Response to thiopurine in inflammatory bowel disease (leukopenia)	1	2	0.5
Helping behaviour (self reported)	2	6	0.333333333333333
Severe gingival inflammation	1	5	0.2
PR interval in Tripanosoma cruzi seropositivity	15	102	0.147058823529412
Positive affect	7	30	0.233333333333333
Fear of medical pain (dental)	3	5	0.6
Number of children	1	8	0.125
Conotruncal heart defects	3	11	0.272727272727273
Systolic blood pressure in sickle cell anemia	2	10	0.2
Response to paliperidone in schizophrenia (PANSS score)	4	61	0.0655737704918033
Esophageal squamous cell carcinoma	3	10	0.3
Diastolic blood pressure response to hydrochlorothiazide in hypertension	1	8	0.125
Electrodermal activity	1	13	0.0769230769230769
Type 2 diabetes nephropathy	1	6	0.166666666666667
Loneliness	4	22	0.181818181818182
Gallbladder cancer	2	7	0.285714285714286
Neuritic plaques or neurofibrillary tangles (pleiotropy)	1	4	0.25
Sarcoidosis	3	12	0.25
Mitochondrial DNA levels	9	21	0.428571428571429
Drug-induced liver injury (flucloxacillin)	1	6	0.166666666666667
Urate levels in lean individuals	7	36	0.194444444444444
Breast cancer (estrogen-receptor negative)	17	73	0.232876712328767
Suicidal ideation in depression or bipolar disorder	1	1	1
Blood trace element (Se levels)	2	10	0.2
Infant length	4	15	0.266666666666667
Macrophage inflammatory protein 1a levels	1	22	0.0454545454545455
Duodenal ulcer	1	2	0.5
Modified Stumvoll Insulin Sensitivity Index (BMI interaction)	1	12	0.0833333333333333
Menopause (age at onset)	33	95	0.347368421052632
Initial pursuit acceleration in psychotic disorders	5	22	0.227272727272727
Type 2 diabetes and other traits	3	6	0.5
Response to statin therapy	9	38	0.236842105263158
Renal overload gout	2	5	0.4
Response to platinum-based chemotherapy (cisplatin)	5	21	0.238095238095238
Corticobasal degeneration	1	8	0.125
Crohn's disease	119	477	0.249475890985325
Systemic sclerosis (anti-centromere-positive)	3	5	0.6
Urate levels	15	79	0.189873417721519
Prostate-specific antigen levels	17	114	0.149122807017544
Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid)	5	20	0.25
Objective response to lithium treatment	1	4	0.25
Cerebrospinal fluid biomarker levels	12	65	0.184615384615385
Gut microbiota (bacterial taxa)	16	72	0.222222222222222
Attention function in attention deficit hyperactive disorder	7	24	0.291666666666667
Response to selective serotonin reuptake inhibitors and depression	1	5	0.2
Brain volume in infants (white matter)	1	6	0.166666666666667
Partial epilepsies	2	6	0.333333333333333
Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer	1	7	0.142857142857143
Atopic march	1	7	0.142857142857143
Bone mineral density (wrist)	1	1	1
Anticoagulant levels	2	8	0.25
Iron status biomarkers (ferritin levels)	2	16	0.125
Response to haloperidol in psychosis	1	2	0.5
Iris color (L* coordinate)	1	13	0.0769230769230769
Hyperactive-impulsive symptoms	2	14	0.142857142857143
Adiposity	3	8	0.375
Stroke (pediatric)	1	4	0.25
AIDS	1	7	0.142857142857143
Blood pressure (smoking interaction)	9	37	0.243243243243243
Quantitative traits	6	33	0.181818181818182
Lewy body disease	10	31	0.32258064516129
Irritable bowel syndrome	3	4	0.75
Insulin levels in response to oral glucose tolerance test (30 minutes)	2	3	0.666666666666667
Sleep-related phenotypes	2	5	0.4
Systemic lupus erythematosus or rheumatoid arthritis	4	9	0.444444444444444
Cerebral amyloid angiopathy	1	6	0.166666666666667
Cleft palate	1	7	0.142857142857143
Response to antipsychotic therapy (extrapyramidal side effects)	4	18	0.222222222222222
Pulmonary function decline	11	39	0.282051282051282
Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel)	3	8	0.375
Serum albumin level	8	16	0.5
Follicular lymphoma	3	14	0.214285714285714
QT interval (ambient particulate matter interaction)	2	6	0.333333333333333
Limited cutaneous systemic scleroderma	4	18	0.222222222222222
Adiponectin levels	13	63	0.206349206349206
Granulocyte percentage of myeloid white cells	33	213	0.154929577464789
Non-cardia gastric cancer	3	8	0.375
Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel)	3	5	0.6
Macrophage inflammatory protein 1b levels	8	104	0.0769230769230769
QT interval (sulfonylurea treatment interaction)	2	12	0.166666666666667
Primary biliary cirrhosis	13	69	0.188405797101449
Eye morphology	1	5	0.2
Cotinine glucuronidation	2	14	0.142857142857143
White blood cell count (basophil)	18	81	0.222222222222222
Economic and political preferences (fairness)	1	7	0.142857142857143
Amyotrophic lateral sclerosis (age of onset)	2	13	0.153846153846154
Immunoglobulin light chain (AL) amyloidosis (heart and kidney involvement)	1	1	1
P wave terminal force	1	12	0.0833333333333333
Non-response to selective serotonin reuptake inhibitors and depression	1	5	0.2
Immune response to anthrax vaccine	1	8	0.125
High light scatter reticulocyte count	38	198	0.191919191919192
Coronary artery disease or large artery stroke	3	17	0.176470588235294
QRS duration	19	128	0.1484375
Paclitaxel-induced neuropathy	1	10	0.1
Pneumococcal bacteremia	1	9	0.111111111111111
Age-related macular degeneration (choroidal neovascularisation)	1	6	0.166666666666667
Retinopathy in non-diabetics	2	11	0.181818181818182
Asparaginase-induced acute pancreatitis in acute lymphoblastic leukemia (onset time)	1	10	0.1
Lipoprotein (a) - cholesterol levels	4	15	0.266666666666667
Carotid intima media thickness	3	23	0.130434782608696
Ileal carcinoids	1	4	0.25
Differentiated thyroid cancer	1	10	0.1
Cerebrospinal fluid clusterin levels in APOEe4- carriers	1	1	1
Attention deficit hyperactivity disorder and conduct disorder	4	26	0.153846153846154
Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels)	2	15	0.133333333333333
Interleukin-13 levels	2	33	0.0606060606060606
Autoimmune thyroid diseases (Graves disease or Hashimoto's thyroiditis)	5	10	0.5
Cognitive function	13	82	0.158536585365854
Body mass index in non-asthmatics	3	9	0.333333333333333
Epilepsy and lamotrigine-induced maculopapular eruptions	4	27	0.148148148148148
Left ventricular mass	1	3	0.333333333333333
Preschool internalizing problems	2	13	0.153846153846154
Alloimmunization response to red blood cell transfusion in sickle cell anemia	1	1	1
Ovarian cancer	5	28	0.178571428571429
Drug-induced liver injury (anti-tuberculosis drugs)	1	3	0.333333333333333
Neuroblastoma	1	10	0.1
Lobe attachment (rater scored)	2	19	0.105263157894737
Ratio of the area under the curve for insulin and the area under the curve for glucose	1	1	1
Exploratory eye movement dysfunction in schizophrenia (responsive search score)	2	21	0.0952380952380952
Anthropometric traits in newborns	1	5	0.2
Bone mineral density change response to combined chemotherapy in acute lymphoblastic leukemia	1	4	0.25
Plasma omega-3 polyunsaturated fatty acid levels (alphalinolenic acid)	2	19	0.105263157894737
Very long-chain saturated fatty acid levels (fatty acid 20:0)	6	21	0.285714285714286
Migraine with aura	2	23	0.0869565217391304
Aortic root size	5	21	0.238095238095238
Urinary metabolites (H-NMR features)	11	39	0.282051282051282
Schizophrenia, bipolar disorder and depression (combined)	2	5	0.4
Venous thromboembolism	4	44	0.0909090909090909
Metabolic syndrome	11	49	0.224489795918367
Vascular brain injury	3	14	0.214285714285714
Lachrymal/Salivary gland lesion in type 1 autoimmune pancreatitis	1	2	0.5
Social communication problems	2	21	0.0952380952380952
Complement C3 and C4 levels	4	10	0.4
Fuchs's corneal dystrophy	2	8	0.25
Paclitaxel disposition in epithelial ovarian cancer	2	31	0.0645161290322581
Nonsyndromic cleft lip with or without cleft palate	2	19	0.105263157894737
Alcoholism (alcohol use disorder factor score)	1	6	0.166666666666667
Smoking initiation	8	27	0.296296296296296
Age at voice drop	2	14	0.142857142857143
Serum vitamin D-binding protein levels	2	3	0.666666666666667
Subjective response to lithium treatment in bipolar disorder	1	4	0.25
Mean arterial pressure	2	13	0.153846153846154
Waist-hip ratio	29	105	0.276190476190476
circulating leptin levels	3	10	0.3
Brain imaging	3	12	0.25
Refractive astigmatism	4	17	0.235294117647059
Osteoprotegerin levels	1	4	0.25
Developmental language disorder	3	4	0.75
Mean platelet volume	55	356	0.154494382022472
Kidney disease (late stage) in type 1 diabetes	1	1	1
Endometrial endometrioid carcinoma	2	7	0.285714285714286
Functional MRI	1	2	0.5
Blood pressure (age interaction)	2	3	0.666666666666667
Antineutrophil cytoplasmic antibody-associated vasculitis	5	24	0.208333333333333
Thyroid peroxidase antibody levels	1	5	0.2
Radiation response	3	12	0.25
Post traumatic stress disorder symptom count in trauma-exposed individuals	1	1	1
Body mass index (change over time) in cancer or chronic obstructive pulmonary disease	2	3	0.666666666666667
Interleukin-6 levels	1	29	0.0344827586206897
Insomnia (caffeine-induced)	2	9	0.222222222222222
Cerebrospinal fluid clusterin levels	4	24	0.166666666666667
Iron status biomarkers (iron levels)	3	24	0.125
Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 3 peripheral neuropathy)	6	16	0.375
Oropharynx cancer	2	17	0.117647058823529
Vitiligo	23	94	0.24468085106383
Alanine transaminase levels	1	1	1
Type 1 diabetes	51	170	0.3
Number of children ever born	2	5	0.4
Prostate cancer (SNP x SNP interaction)	27	102	0.264705882352941
Fasting blood insulin	2	12	0.166666666666667
Testosterone levels in polycystic ovary syndrome	1	4	0.25
Attention deficit hyperactivity disorder	21	96	0.21875
Postoperative atrial fibrillation in coronary artery bypass grafting surgery	1	3	0.333333333333333
Triglyceride levels	15	70	0.214285714285714
Manic episodes in bipolar disorder	1	3	0.333333333333333
Vascular endothelial growth factor levels	8	54	0.148148148148148
Creatinine levels in ischemic stroke	1	6	0.166666666666667
Ovarian reserve	1	7	0.142857142857143
Hypospadias	8	25	0.32
Body mass (lean)	1	2	0.5
HIV-associated neurocognitive disorder	1	2	0.5
AIDS progression	2	10	0.2
Metabolite levels (Dihydroxy docosatrienoic acid)	5	20	0.25
Body mass index (joint analysis main effects and physical activity interaction)	53	242	0.21900826446281
Sum eosinophil basophil counts	32	198	0.161616161616162
Intracranial volume	1	2	0.5
Major depression and alcohol dependence	6	47	0.127659574468085
Iris heterochromicity	1	5	0.2
Sleep quality	1	7	0.142857142857143
Incident myocardial infarction	1	4	0.25
Cardiovascular disease risk factors	3	24	0.125
Non-obstructive azoospermia	1	5	0.2
Autism spectrum disorder or schizophrenia	28	301	0.0930232558139535
Frontotemporal dementia (age at onset)	1	1	1
Glaucoma (low intraocular pressure)	2	3	0.666666666666667
Alzheimer's disease biomarkers	7	25	0.28
Free thyroxine concentration	1	3	0.333333333333333
Sarcoidosis (non-Lofgren's syndrome without extrapulmonary manifestations)	1	5	0.2
Neutrophil percentage of granulocytes	23	168	0.136904761904762
Melanoma	9	55	0.163636363636364
Ovarian cancer in BRCA1 mutation carriers	2	11	0.181818181818182
Age-related diseases, mortality and associated endophenotypes	5	44	0.113636363636364
Exploratory eye movement dysfunction in schizophrenia (cognitive search score)	3	15	0.2
BMI in non-smokers	18	105	0.171428571428571
Pediatric nonalcoholic steatohepatitis	1	2	0.5
Response to anti-depressant treatment in major depressive disorder	6	22	0.272727272727273
Response to dabigatran etexilate treatment	1	2	0.5
Delta-6 desaturase activity response to n3-polyunsaturated fat supplement	1	1	1
Ratio of apolipoprotein A1 to apolipoprotein B	1	1	1
White matter lesion progression	2	7	0.285714285714286
Diffuse large B cell lymphoma	3	8	0.375
Childhood body mass index	5	39	0.128205128205128
Fear of severe pain	3	8	0.375
Urinary metabolites	10	25	0.4
Blood trace element (Cu levels)	2	7	0.285714285714286
Hair morphology	2	15	0.133333333333333
Erythema nodosum in inflammatory bowel disease	3	5	0.6
Mitral valve prolapse	1	8	0.125
Myringotomy	4	34	0.117647058823529
Blood osmolality (transformed sodium)	7	37	0.189189189189189
Visceral fat	10	40	0.25
Lung cancer in never smokers	3	23	0.130434782608696
Atopic dermatitis	13	82	0.158536585365854
Binge eating behaviour and bipolar disorder	1	7	0.142857142857143
Loneliness (multivariate analysis)	4	19	0.210526315789474
Interleukin-2 levels	4	26	0.153846153846154
Optic cup area	11	93	0.118279569892473
Response to antipsychotic treatment in schizophrenia (reasoning)	3	10	0.3
Cerebrospinal T-tau levels	2	30	0.0666666666666667
Major depressive disorder (broad)	1	9	0.111111111111111
Serum metabolite concentrations in chronic kidney disease	6	40	0.15
Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease	1	5	0.2
Smoking behavior	11	46	0.239130434782609
Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (dichotomous)	1	3	0.333333333333333
Lifespan	1	9	0.111111111111111
Eotaxin levels	6	46	0.130434782608696
Sleep depth	1	2	0.5
Plasma omega-6 polyunsaturated fatty acid levels (arachidonic acid)	5	23	0.217391304347826
Post-traumatic stress disorder (asjusted for relatedness)	5	19	0.263157894736842
Cannabis dependence symptom count	2	37	0.0540540540540541
Triglyceride levels in small VLDL	1	20	0.05
Breast Cancer in BRCA1 mutation carriers	3	16	0.1875
Breast cancer (early onset)	6	18	0.333333333333333
Chronotype	5	39	0.128205128205128
Febrile seizures (MMR vaccine-related)	1	10	0.1
Hip circumference (psychosocial stress interaction)	1	5	0.2
Large artery stroke	2	14	0.142857142857143
Relative hand skill in reading disability	3	10	0.3
Bone mineral density (paediatric, total body less head)	7	25	0.28
Airflow obstruction	3	31	0.0967741935483871
Hand grip strength	4	25	0.16
Waist-to-hip circumference ratio (ever vs never smoking interaction)	1	3	0.333333333333333
Dengue shock syndrome	1	4	0.25
Word reading	1	15	0.0666666666666667
Dupuytren's disease	9	41	0.219512195121951
Idiopathic osteonecrosis of the femoral head	1	10	0.1
Heart rate	8	39	0.205128205128205
Tonometry	4	13	0.307692307692308
Platelet aggregation	4	15	0.266666666666667
Allergic dermatitis (nickel)	1	2	0.5
Ankle injury	7	38	0.184210526315789
Ovarian clear cell cancer	1	2	0.5
Male fertility	1	6	0.166666666666667
Macrophage colony stimulating factor levels	1	23	0.0434782608695652
Celiac disease or Rheumatoid arthritis	3	15	0.2
Blood pressure	19	119	0.159663865546218
Serum VEGFR2 concentration	1	1	1
Liver injury in combined anti-retroviral and anti-tuberculosis drug-treated HIV with tuberculosis	1	3	0.333333333333333
Autoimmune hepatitis type-1	1	3	0.333333333333333
Otitis media (chronic)	1	2	0.5
Facial morphology (factor 15, philtrum width)	1	26	0.0384615384615385
Behavioral disturbance or psychiatric symptoms and prion disease	1	3	0.333333333333333
Age of smoking initiation	3	8	0.375
Phytosterol levels	1	3	0.333333333333333
Facial morphology (factor 6, height of vermillion lower lip)	3	22	0.136363636363636
Response to radiotherapy in prostate cancer (toxicity, urinary frequency)	1	11	0.0909090909090909
Creutzfeldt-Jakob disease	1	2	0.5
Metabolite levels (Pyroglutamine)	6	23	0.260869565217391
Nodular sclerosis Hodgkin lymphoma	1	17	0.0588235294117647
Psoriasis	52	194	0.268041237113402
Helix rolling	1	6	0.166666666666667
Low density lipoprotein cholesterol	1	2	0.5
Kidney disease (end stage renal disease vs non-end stage renal disease) in type 1 diabetes	1	2	0.5
Thionamide-induced agranulocytosis in Graves' disease	2	9	0.222222222222222
Toenail selenium levels	5	16	0.3125
Intelligence (MTAG)	102	645	0.158139534883721
Factor VII levels	1	2	0.5
Dental caries	10	69	0.144927536231884
Language performance in older adults (adjusted for episodic memory)	2	8	0.25
Nonalcoholic steatohepatitis-derived hepatocellular carcinoma	1	3	0.333333333333333
Food addiction	2	10	0.2
Hypothyroidism	13	45	0.288888888888889
Contrast sensitivity	1	5	0.2
Scoliosis	1	3	0.333333333333333
Symmetrical dimethylarginine levels	4	31	0.129032258064516
Estradiol levels	1	8	0.125
Response to cognitive-behavioural therapy in anxiety disorder	2	12	0.166666666666667
Hashimoto thyroiditis	1	1	1
Joint mobility (Beighton score)	2	25	0.08
Pre bronchodilator FEV1/FVC ratio	4	12	0.333333333333333
Response to TNF antagonist treatment	3	8	0.375
Immune reponse to smallpox (secreted IL-12p40)	2	10	0.2
Antibody status in Tripanosoma cruzi seropositivity	3	20	0.15
Primary tooth development (number of teeth)	5	20	0.25
Cardiovascular risk factors	1	2	0.5
Age at first birth	8	22	0.363636363636364
Subcortical brain region volumes	1	12	0.0833333333333333
Congenital heart disease	1	2	0.5
Depressive symptoms	8	33	0.242424242424242
Refractive error	8	29	0.275862068965517
Facial morphology (factor 1, breadth of lateral portion of upper face)	4	21	0.19047619047619
Granulocyte-colony stimulating factor levels	2	20	0.1
Hip circumference adjusted for BMI	37	225	0.164444444444444
middle facial morphology traits (quantitative measurement)	3	7	0.428571428571429
Response to antipsychotic treatment in schizophrenia (working memory)	3	11	0.272727272727273
Neuritic plaques or cerebral amyloid angiopathy (pleiotropy)	1	3	0.333333333333333
Glycated hemoglobin levels	33	111	0.297297297297297
Dialysis-related mortality	6	26	0.230769230769231
Addiction	2	16	0.125
Bladder cancer	11	31	0.354838709677419
Paget's disease	6	13	0.461538461538462
Waist Circumference - Triglycerides (WC-TG)	1	7	0.142857142857143
Tourette's syndrome or obsessive-compulsive disorder	3	15	0.2
Response to metformin in type 2 diabetes (HbA1c reduction)	1	1	1
Carboplatin disposition in epthelial ovarian cancer	4	18	0.222222222222222
Facial morphology (factor 13, vertical position of alar curvature relative to upper lip)	1	16	0.0625
Mean corpuscular volume	83	416	0.199519230769231
White matter integrity (bipolar disorder risk interaction)	2	6	0.333333333333333
Immunoglobulin light chain (AL) amyloidosis (serum Ig lambda profile)	1	2	0.5
Egg allergy	1	5	0.2
Number of children (6+ vs. 0 or 1)	2	11	0.181818181818182
Length of menstrual cycle	1	2	0.5
Head circumference (infant)	1	3	0.333333333333333
Psychosis and Alzheimer's disease	3	11	0.272727272727273
Homeostasis model assessment of insulin resistance (dietary factor interaction)	2	15	0.133333333333333
Loneliness (linear analysis)	2	18	0.111111111111111
Urate levels in obese individuals	5	35	0.142857142857143
Circulating myeloperoxidase levels (plasma)	2	3	0.666666666666667
Thrombosis	1	13	0.0769230769230769
Response to amphetamines	16	88	0.181818181818182
Hippocampal atrophy	9	34	0.264705882352941
Optic nerve measurement (cup area)	2	9	0.222222222222222
Fractional exhaled nitric oxide levels	1	2	0.5
Coronary artery disease (myocardial infarction, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease)	17	72	0.236111111111111
Pulmonary function (smoking interaction)	13	53	0.245283018867925
Otitis media	1	4	0.25
diarrhoeal disease at age 2 with doctor diagnosis	1	1	1
Exudative age-related macular degeneration	2	7	0.285714285714286
Tooth agenesis (maxillary lateral incisors)	1	2	0.5
Idiopathic pulmonary fibrosis	1	13	0.0769230769230769
Isovolumetric relaxation time	3	5	0.6
QRS complex (Cornell)	2	17	0.117647058823529
Functional impairment in major depressive disorder, bipolar disorder and schizophrenia	1	5	0.2
Entorhinal cortical thickness	1	5	0.2
Total body bone mineral density (age 45-60)	1	18	0.0555555555555556
Non-glioblastoma glioma	7	30	0.233333333333333
Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid)	5	25	0.2
Survival in colon cancer	2	12	0.166666666666667
E-selectin levels	1	1	1
Perioperative myocardial infarction in coronary artery bypass surgery	4	25	0.16
Intracranial aneurysm	5	50	0.1
Arthritis (juvenile idiopathic)	2	7	0.285714285714286
Gamma glutamyl transferase levels	1	4	0.25
Virologic severity in Herpes simplex virus type 2 infection	2	12	0.166666666666667
Gallstone disease	2	7	0.285714285714286
Gestational age at birth (child effect)	3	13	0.230769230769231
Asthma	46	200	0.23
Coffee consumption	3	20	0.15
Waist-to-hip circumference ratio (smoking years interaction)	1	3	0.333333333333333
N-glycan levels	38	49	0.775510204081633
Attention deficit hyperactivity disorder (inattention symptoms)	5	22	0.227272727272727
Intraocular pressure	74	462	0.16017316017316
Response to tocilizumab in rheumatoid arthritis	3	28	0.107142857142857
Acute lymphoblastic leukemia (childhood)	13	72	0.180555555555556
Iron status biomarkers (transferrin saturation)	2	38	0.0526315789473684
Pelvic organ prolapse	4	25	0.16
Cognitive decline (age-related)	3	21	0.142857142857143
QRS complex (Sokolow-Lyon)	1	9	0.111111111111111
Plasma clusterin levels	1	15	0.0666666666666667
Facial morphology (factor 16)	1	15	0.0666666666666667
Response to platinum-based neoadjuvant chemotherapy in cervical cancer	1	3	0.333333333333333
Monocyte chemoattractant protein-1 (red blood cell fatty acid level interaction)	1	1	1
Pediatric bone mineral density (femoral neck)	2	17	0.117647058823529
Interleukin-4 levels	2	24	0.0833333333333333
Skin colour saturation	2	14	0.142857142857143
Schizophrenia (treatment resistant)	1	3	0.333333333333333
Fear of minor pain	3	19	0.157894736842105
Urinary bladder cancer	4	7	0.571428571428571
Weight loss (gastric bypass surgery)	3	12	0.25
Lung function (maximal voluntary ventilation)	1	3	0.333333333333333
Response to statins (LDL cholesterol change)	3	14	0.214285714285714
Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy)	2	5	0.4
Alcoholism (12-month weekly alcohol consumption)	1	2	0.5
Pericardial fat	2	3	0.666666666666667
Plantar warts	3	59	0.0508474576271186
Osteosarcoma	2	6	0.333333333333333
Age-related disease endophenotypes	3	31	0.0967741935483871
IgE levels in asthmatics (D.f. specific)	1	2	0.5
Facial morphology (factor 11, projection of the nose)	3	19	0.157894736842105
Allergy	3	26	0.115384615384615
Cannabis use (initiation)	4	20	0.2
LDL peak particle diameter (total fat intake interaction)	6	21	0.285714285714286
Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes	5	26	0.192307692307692
Obesity	23	104	0.221153846153846
Bilirubin levels in extreme obesity	1	1	1
Systolic blood pressure change trajectories	3	10	0.3
Invasive epithelial ovarian cancer	2	17	0.117647058823529
Subjective well-being	16	126	0.126984126984127
Congenital heart disease (inherited effect)	2	10	0.2
Pre bronchodilator FEV1	5	12	0.416666666666667
Waist circumference adjusted for BMI in inactive individuals	2	14	0.142857142857143
Glucocorticoid-induced osteonecrosis (age 10 years and older)	2	11	0.181818181818182
Microalbuminuria	2	15	0.133333333333333
Epstein Barr virus nuclear antigen 1 IgG levels	2	9	0.222222222222222
Testicular germ cell tumor	17	126	0.134920634920635
Rheumatic fever	2	24	0.0833333333333333
Yu-Zhi constitution type in type 2 diabetes	2	11	0.181818181818182
Birth weight	18	74	0.243243243243243
Sleep time	1	5	0.2
Longevity (90 years and older)	2	10	0.2
BMI in smokers	9	30	0.3
Facial morphology (factor 2, vertical position of orbits relative to midface)	1	16	0.0625
Soluble ICAM-1	4	7	0.571428571428571
Thiazide-induced adverse metabolic effects in hypertensive patients	9	59	0.152542372881356
Cutaneous squamous cell carcinoma	3	13	0.230769230769231
Response to taxane treatment (placlitaxel)	2	13	0.153846153846154
Mammographic density	1	5	0.2
Exercise treadmill test traits	1	4	0.25
Sleep latency	1	1	1
Response to antidepressant treatment (citalopram)	1	3	0.333333333333333
Response to metformin (IC50)	2	12	0.166666666666667
Vitiligo (non-segmental)	1	1	1
Iris color (a* coordinate)	1	9	0.111111111111111
Systolic blood pressure (cigarette smoking interaction)	2	8	0.25
Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes	6	68	0.0882352941176471
Interleukin-2 receptor antagonist levels	1	27	0.037037037037037
Lower body strength	2	11	0.181818181818182
B-cell malignancies (chronic lymphocytic leukemia, Hodgkin lymphoma or multiple myeloma) (pleiotropy)	1	20	0.05
Mental development (prenatal lead exposure interaction)	1	1	1
Postprandial triglyceride response to high fat diet meal	2	9	0.222222222222222
Conduct disorder (maternal expressed emotions interaction)	3	15	0.2
Esophageal cancer	3	13	0.230769230769231
Venlafaxine response in generalised anxiety disorder (remitters vs non-remitters after 24 weeks)	1	3	0.333333333333333
Western dietary pattern	1	23	0.0434782608695652
Craniofacial microsomia	2	13	0.153846153846154
Bipolar disorder	42	174	0.241379310344828
Left ventricular obstructive tract defect (maternal effect)	1	9	0.111111111111111
Low-grade serous and serous borderline ovarian cancer	2	12	0.166666666666667
Reading and spelling	1	10	0.1
Immature fraction of reticulocytes	33	145	0.227586206896552
Thyroid cancer	5	22	0.227272727272727
Epilepsy (generalized)	2	10	0.2
Seborrheic dermatitis	1	12	0.0833333333333333
Anti-cyclic Citrullinated Peptide Antibody	1	1	1
Blood and toenail selenium levels	3	12	0.25
Pericardial adipose tissue adjusted for height and weight	3	9	0.333333333333333
Presence of antiphospholipid antibodies	2	23	0.0869565217391304
Iron levels	1	1	1
Smoking quantity	1	8	0.125
Overall survival in serous epithelial ovarian cancer treated with paclitaxel and cisplatin	1	10	0.1
Cold sores	3	43	0.0697674418604651
RANTES levels	1	33	0.0303030303030303
Advanced age-related macular degeneration	6	54	0.111111111111111
Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin)	1	3	0.333333333333333
Verbal memory performance (residualized delayed recall level)	1	7	0.142857142857143
Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin)	1	7	0.142857142857143
Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous)	1	4	0.25
Normalized brain volume	1	5	0.2
Metabolic syndrome (bivariate traits)	4	16	0.25
Mammographic density (dense area)	4	12	0.333333333333333
Depressive symptoms measurement (somatic complaints domain)	1	1	1
Immune reponse to smallpox (secreted IL-1beta)	1	13	0.0769230769230769
Kidney disease (end stage renal disease vs normoalbuminuria) in type 1 diabetes	1	1	1
Wilms tumor	1	7	0.142857142857143
Pulmonary emphysema	1	3	0.333333333333333
Plasma amyloid beta peptide concentrations (ABx-40)	3	10	0.3
Chronic periodontitis	1	2	0.5
Adverse response to chemotherapy (neutropenia/leucopenia) (all topoisomerase inhibitors)	1	6	0.166666666666667
Obesity (extreme)	2	17	0.117647058823529
Waist circumference adjusted for BMI in smokers	4	15	0.266666666666667
Body mass index (change over time) in gastrointestinal cancer or chronic obstructive pulmonary disease	1	4	0.25
Strep throat	5	49	0.102040816326531
Acylcarnitine levels	1	15	0.0666666666666667
Serum uric acid levels in response to allopurinol in gout	4	26	0.153846153846154
Acute graft versus host disease in bone marrow transplantation (recipient effect)	4	19	0.210526315789474
Plasma amyloid beta peptide concentrations (ABx-42)	1	8	0.125
Lung cancer (smoking interaction)	1	2	0.5
Serum lycopene concentrations	1	5	0.2
BMI (adjusted for smoking behaviour)	27	145	0.186206896551724
Developmental language disorder (linguistic errors)	2	9	0.222222222222222
Vitamin B12 levels	3	11	0.272727272727273
Type 2 diabetes (age of onset)	4	26	0.153846153846154
Rhegmatogenous retinal detachment	3	4	0.75
Inflammatory biomarkers	5	29	0.172413793103448
Biliary atresia	1	3	0.333333333333333
Nasopharyngeal carcinoma	3	25	0.12
Lung function (FEV1)	6	42	0.142857142857143
Adenocarcinoma	2	5	0.4
Brain imaging in schizophrenia (dorsolateral prefrontal cortex interaction)	3	6	0.5
Seasonality	2	8	0.25
Hepcidin levels	1	15	0.0666666666666667
Dehydroepiandrosterone sulphate levels	2	10	0.2
Waist circumference adjusted for BMI in active individuals	50	235	0.212765957446809
Myasthenia gravis	3	9	0.333333333333333
Sarcoidosis (Lofgren's syndrome vs non-Lofgren's syndrome)	4	23	0.173913043478261
Gambling	1	5	0.2
Smoking cessation in chronic obstructive pulmonary disease	1	8	0.125
Pre-treatment pain in head and neck squamous cell carcinoma	4	9	0.444444444444444
Body mass index (SNP x SNP interaction)	4	11	0.363636363636364
Body mass index in physically active individuals	44	195	0.225641025641026
Bone mineral density (Ward's triangle area)	1	18	0.0555555555555556
Suicidal ideation	1	4	0.25
Bipolar disorder with mood-incongruent psychosis	3	16	0.1875
Premature menopause in childhood cancer survivors	1	8	0.125
Creatinine levels	1	9	0.111111111111111
Plasma trimethylamine N-oxide levels	1	12	0.0833333333333333
Adverse response to chemotherapy in breast cancer (alopecia) (anti-microtubule)	2	7	0.285714285714286
Hair shape	5	11	0.454545454545455
Wegener's granulomatosis	2	6	0.333333333333333
Anger	1	14	0.0714285714285714
Schizophrenia (age at onset)	1	2	0.5
Classic bladder exstrophy	2	25	0.08
Response to citalopram treatment	5	24	0.208333333333333
Renal transplant outcome	1	4	0.25
Influenza A (H1N1) severity	1	7	0.142857142857143
Waist-to-hip ratio adjusted for BMI in active individuals	53	143	0.370629370629371
Response to taxane treatment (docetaxel)	1	16	0.0625
Adverse response to chemotherapy (neutropenia/leucopenia) (camptothecin)	2	3	0.666666666666667
Interleukin-7 levels	2	23	0.0869565217391304
D-dimer levels	2	15	0.133333333333333
Amyotrophic lateral sclerosis (C9orf72 mutation interaction)	1	3	0.333333333333333
Depressive and manic episodes in bipolar disorder	1	7	0.142857142857143
Betaine levels in individuals undergoing cardiac evaluation	1	2	0.5
Pulmonary function in asthmatics	2	10	0.2
Liver enzyme levels (gamma-glutamyl transferase)	9	26	0.346153846153846
Interferon gamma-induced protein 10 levels	1	36	0.0277777777777778
Resistance to antihypertensive treatment in hypertension	1	6	0.166666666666667
Lipoprotein (a) levels	12	79	0.151898734177215
Plateletcrit	38	258	0.147286821705426
Esophageal cancer and gastric cancer	1	4	0.25
Lipoprotein-associated phospholipase A2 activity change in response to darapladib treatment in cardiovascular disease	2	3	0.666666666666667
Periodontal disease-related phenotypes	5	22	0.227272727272727
Plasma androstenedione levels in resected early stage-receptor positive breast cancer	2	5	0.4
Plasminogen activator inhibitor type 1 levels (PAI-1)	1	4	0.25
Electroencephalographic traits in alcoholism	2	8	0.25
Bipolar disorder lithium response (continuous) or schizophrenia	2	8	0.25
Setpoint viral load in HIV-1 infection	2	2	1
Subjective well-being (MTAG)	9	49	0.183673469387755
Schizophrenia (negative symptoms)	1	3	0.333333333333333
Facial morphology (factor 18)	2	20	0.1
Hair color	2	30	0.0666666666666667
Cerebrospinal fluid beta-site APP cleaving enzyme levels	2	8	0.25
Post bronchodilator FEV1 in COPD	9	124	0.0725806451612903
Cannabis dependence	3	11	0.272727272727273
Autism spectrum disorder-related traits	1	6	0.166666666666667
Homoarginine levels	1	1	1
nicotine metabolite ratio in current smokers	2	17	0.117647058823529
Bone mineral density	19	130	0.146153846153846
Pyoderma gangrenosum in inflammatory bowel disease	1	7	0.142857142857143
Anti-thyroid drug induced agranulocytosis	1	4	0.25
Metabolic traits	7	48	0.145833333333333
Response to chemotherapy in breast cancer (hypertension) (bevacizumab)	1	3	0.333333333333333
Response to angiotensin II receptor blocker therapy	3	20	0.15
Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL)	8	54	0.148148148148148
Gamma glutamyl transpeptidase	2	7	0.285714285714286
Immune reponse to smallpox (secreted IL-2)	5	17	0.294117647058824
Childhood ear infection	19	116	0.163793103448276
Fasting plasma glucose (childhood)	1	1	1
Carotid plaque burden	2	39	0.0512820512820513
Verbal-numerical reasoning	1	2	0.5
Incident atrial fibrillation	1	5	0.2
Age-related macular degeneration	9	98	0.0918367346938776
Multiple myeloma (IgH translocation)	4	25	0.16
Protein biomarker	1	2	0.5
IgG N-glycosylation phenotypes (multivariate analysis)	1	9	0.111111111111111
Response to antineoplastic agents	1	9	0.111111111111111
Body mass index	284	1374	0.20669577874818
Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy)	51	244	0.209016393442623
Caffeine metabolism (plasma 1,7-dimethylxanthine (paraxanthine) to 1,3,7-trimethylxanthine (caffeine) ratio)	4	31	0.129032258064516
Cholesterol, total	51	227	0.224669603524229
Obstructive sleep apnea trait (average respiratory event duration)	1	14	0.0714285714285714
Esophageal cancer  (alcohol interaction)	3	4	0.75
Scarlet fever	7	54	0.12962962962963
Maximal oxygen uptake response	3	4	0.75
Otitis media (chronic/recurrent)	1	1	1
Interferon gamma levels	3	29	0.103448275862069
Polycystic ovary syndrome	6	35	0.171428571428571
Attention deficit hyperactivity disorder (time to onset)	2	11	0.181818181818182
Bipolar I disorder	1	2	0.5
Sepsis in extremely premature infants	1	5	0.2
Major depressive disorder	46	285	0.16140350877193
Behavioural disinhibition (generation interaction)	5	20	0.25
Facial morphology (factor 17, height of vermillion upper lip)	2	25	0.08
Middle childhood and early adolescence aggressive behavior	3	7	0.428571428571429
Conotruncal heart defects (inherited effects)	1	10	0.1
Thyroid peroxidase antibody positivity	2	11	0.181818181818182
HDL cholesterol levels	24	111	0.216216216216216
Idiopathic intracranial hypertension	1	15	0.0666666666666667
White blood cell count (neutrophil)	1	4	0.25
Chronic obstructive pulmonary disease (moderate to severe)	2	9	0.222222222222222
Folate pathway vitamin levels	2	14	0.142857142857143
Parent of origin effect on language impairment (paternal)	1	4	0.25
Lung function (FEV1/FVC)	7	64	0.109375
Lentiform nucleus volume	6	14	0.428571428571429
Colorectal or endometrial cancer	3	29	0.103448275862069
Central corneal thickness	12	72	0.166666666666667
Percentage gas trapping	3	17	0.176470588235294
Cardiovascular risk factors (age interaction)	1	4	0.25
Metabolite levels (HVA)	1	13	0.0769230769230769
Bipolar disorder (age of onset <21) or attention deficit hyperactivity disorder	2	6	0.333333333333333
Heart rate variability traits (SDNN)	4	26	0.153846153846154
HDL cholesterol	62	306	0.202614379084967
Prostate cancer	58	293	0.197952218430034
Pelvic organ prolapse (moderate/severe)	2	33	0.0606060606060606
Neutrophil percentage of white cells	14	132	0.106060606060606
Homeostasis model assessment of beta-cell function (dietary factor interaction)	4	12	0.333333333333333
Triglycerides	38	209	0.181818181818182
Hepatitis B vaccine response	2	5	0.4
HDL cholesterol change in response to fenofibrate in statin-treated type 2 diabetes	1	6	0.166666666666667
Liver injury in anti-tuberculosis drug treatment	1	2	0.5
Lead levels in blood	1	15	0.0666666666666667
Hodgkin's lymphoma	6	28	0.214285714285714
Liver enzyme levels (alkaline phosphatase)	4	14	0.285714285714286
Neuritic plaque	4	20	0.2
Pediatric bone mineral content (radius)	4	24	0.166666666666667
Peanut allergy (parent-of-origin effect)	1	5	0.2
Suicide behavior	3	5	0.6
Insulin resistance/response	4	15	0.266666666666667
Bone mineral density (spine)	6	46	0.130434782608696
General cognitive ability	1	3	0.333333333333333
Ejection fraction in Tripanosoma cruzi seropositivity	4	25	0.16
Body mass index (change over time) in lung cancer	1	3	0.333333333333333
Hip circumference	19	142	0.133802816901408
Whole-brain volume (Alzheimer's disease interaction)	1	4	0.25
Plasma neurofilament light levels	1	2	0.5
Caudate activity during reward	5	30	0.166666666666667
Rheumatoid arthritis (ACPA-positive)	12	56	0.214285714285714
Panic disorder	2	17	0.117647058823529
Magnesium levels	8	31	0.258064516129032
Response to fenofibrate (adiponectin levels)	6	12	0.5
Hematology traits	3	23	0.130434782608696
Volumetric brain MRI	2	5	0.4
Breast cancer (male)	1	3	0.333333333333333
Severe influenza A (H1N1) infection	1	34	0.0294117647058824
IgE levels in asthmatics	2	4	0.5
Longevity (85 years and older)	1	4	0.25
Facial emotion recognition	2	3	0.666666666666667
Verbal memory performance (immediate recall change)	2	4	0.5
Homeostasis model assessment of beta-cell function	1	10	0.1
Food allergy	1	7	0.142857142857143
Photic sneeze reflex	7	49	0.142857142857143
Psoriatic arthritis	3	19	0.157894736842105
Protein quantitative trait loci	12	49	0.244897959183673
Thyroid stimulating hormone	2	4	0.5
Liver enzyme levels (alanine transaminase)	3	15	0.2
Total triglycerides levels	1	20	0.05
beta-nerve growth factor levels	2	26	0.0769230769230769
Lung disease severity in cystic fibrosis	7	29	0.241379310344828
Left  ventricle systolic dysfunction	3	6	0.5
Fast beta electroencephalogram	1	6	0.166666666666667
Menarche and menopause (age at onset)	1	6	0.166666666666667
Obstructive sleep apnea trait (apnea hypopnea index)	1	42	0.0238095238095238
Venlafaxine response in generalised anxiety disorder (HAMA-A score reduction after 24 weeks)	1	2	0.5
Renal function-related traits (sCR)	4	9	0.444444444444444
Heart rate response to beta blockers (atenolol monotherapy)	5	29	0.172413793103448
Total ventricular volume (Alzheimer's disease interaction)	4	11	0.363636363636364
Non-alcoholic fatty liver disease histology (AST)	1	6	0.166666666666667
Alzheimer's disease (late onset)	19	90	0.211111111111111
Serum tamsulosin hydrochloride concentration	1	4	0.25
Optic nerve measurement (cup-to-disc ratio)	2	8	0.25
Bone properties (heel)	6	20	0.3
Response to simvastatin treatment (PCSK9 protein level change)	3	7	0.428571428571429
IgE levels	7	18	0.388888888888889
Hepatitis A	2	36	0.0555555555555556
B-type natriuretic peptide levels	1	3	0.333333333333333
Attention deficit hyperactivity disorder symptoms (maternal expressed emotions interaction)	2	7	0.285714285714286
Forced expiratory volume in 1 second (occupational environmental exposures interaction)	1	7	0.142857142857143
Resting heart rate	16	106	0.150943396226415
Alzheimer's disease in APOE e4+ carriers	2	17	0.117647058823529
Fractional exhaled nitric oxide (childhood)	11	25	0.44
Glioblastoma	5	21	0.238095238095238
Hereditary hemochromatosis-related traits (HFE mutation homozygotes)	2	2	1
Educational attainment (years of education)	18	162	0.111111111111111
Common carotid intima-media thickness in HIV negative individuals	3	13	0.230769230769231
Liver enzyme levels (aspartate transaminase)	1	8	0.125
Otitis media (recurrent)	1	4	0.25
Response to antidepressants and depression	1	5	0.2
Essential tremor	4	14	0.285714285714286
Bipolar disorder and schizophrenia	22	122	0.180327868852459
Squamous cell carcinoma	2	18	0.111111111111111
Systolic blood pressure (dietary potassium intake interaction)	1	1	1
Colonoscopy-negative controls vs population controls	32	131	0.244274809160305
Left superior temporal gyrus thickness (schizophrenia interaction)	3	6	0.5
Bone mineral density (paediatric, lower limb)	2	11	0.181818181818182
Fetal hemoglobin levels	1	5	0.2
Congenital left-sided heart lesions (maternal effect)	1	1	1
Speech perception in dyslexia	1	2	0.5
Facial emotion recognition (sad faces)	2	4	0.5
Interferon alpha levels in systemic lupus erythematosus	2	8	0.25
Severe malaria (adjusted for sickle cell variant rs334)	1	14	0.0714285714285714
Serous invasive ovarian cancer	3	19	0.157894736842105
White blood cell count	40	218	0.18348623853211
Cortisol levels (saliva)	1	10	0.1
Myocardial infarction (early onset)	3	9	0.333333333333333
Parkinson disease and lewy body pathology	1	10	0.1
Obstructive sleep apnea (average oxygen saturation during sleep)	3	5	0.6
Diabetic kidney disease	10	58	0.172413793103448
Monocyte count	45	258	0.174418604651163
Gait rhythm	2	5	0.4
Body fat percentage	14	53	0.264150943396226
Medication adherence in chronic diseases	1	2	0.5
Waist circumference adjusted for BMI in non-smokers	21	108	0.194444444444444
Proteinuria and chronic kidney disease	1	9	0.111111111111111
PR segment	1	8	0.125
Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder	7	34	0.205882352941176
Lipid metabolism phenotypes	31	91	0.340659340659341
Thyroid hormone levels	12	60	0.2
Primary biliary cholangitis	27	108	0.25
Male-pattern baldness	14	114	0.12280701754386
Familial hepatitis B virus-related hepatocellular carcinoma	2	4	0.5
Body mass index (change over time) in cancer	1	1	1
Mortality in sepsis	3	15	0.2
Serum parathyroid hormone levels	2	6	0.333333333333333
Bulimia nervosa	1	23	0.0434782608695652
Hyperuricemia	2	2	1
Reading or mathematical ability	1	2	0.5
Bone ultrasound measurement (broadband ultrasound attenuation)	5	28	0.178571428571429
Hippocampal volume	4	29	0.137931034482759
Metabolite levels (small molecules and protein measures)	8	32	0.25
White blood cell count (eosinophil)	1	5	0.2
Mucinous ovarian carcinoma	2	13	0.153846153846154
Major coronary event in cardiovascular disease (time to event) (darapladib treatment interaction)	1	5	0.2
Carotenoid levels (alpha-carotene)	2	3	0.666666666666667
Venous thromboembolism adjusted for sickle cell variant rs77121243-T	13	81	0.160493827160494
Sum basophil neutrophil counts	28	148	0.189189189189189
Renal cell carcinoma	9	41	0.219512195121951
Economic and political preferences (time)	1	10	0.1
Rheumatoid arthritis	71	351	0.202279202279202
Cognitive ability (MTAG)	21	82	0.25609756097561
Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction)	55	141	0.390070921985816
Response to platinum-based agents	2	3	0.666666666666667
Selective IgA deficiency	2	33	0.0606060606060606
Interleukin-17 levels	1	34	0.0294117647058824
IgG glycosylation patterns	44	309	0.142394822006472
Coronary artery disease or ischemic stroke	3	14	0.214285714285714
Alcohol dependence	20	120	0.166666666666667
Alzheimer's disease (survival time)	1	7	0.142857142857143
Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy)	4	13	0.307692307692308
Immune response to measles-mumps-rubella vaccine	1	10	0.1
HIV-1 replication	1	1	1
Obesity (early onset extreme)	2	24	0.0833333333333333
Basophil percentage of white cells	9	63	0.142857142857143
Obstetric antiphospholipid syndrome	3	15	0.2
Fasting insulin (dietary factor interaction)	2	14	0.142857142857143
HIV-associated neurocognitive disorder (asymptomatic neurocogntive impairment)	2	3	0.666666666666667
Expressive vocabulary in infants	2	8	0.25
Immunoglobulin light chain (AL) amyloidosis (heart involvement)	1	1	1
Post bronchodilator FEV1/FVC ratio in COPD	39	473	0.0824524312896406
Asperger disorder	1	5	0.2
Depression	2	15	0.133333333333333
Preeclampsia	3	18	0.166666666666667
Waist-to-hip ratio adjusted for body mass index	116	465	0.249462365591398
Response to interferon beta in multiple sclerosis	1	3	0.333333333333333
Eating disorders (purging via substances)	2	11	0.181818181818182
Bacterial meningitis	1	38	0.0263157894736842
Asparaginase hypersensitivity in acute lymphoblastic leukemia	2	9	0.222222222222222
Serum 25-Hydroxyvitamin D levels	1	2	0.5
Opioid sensitivity	1	4	0.25
Cleft lip with or without cleft palate	3	32	0.09375
Pediatric non-alcoholic fatty liver disease activity score	2	5	0.4
Food allergy (parent-of-origin effect)	2	6	0.333333333333333
Number of pregnancies	2	12	0.166666666666667
Granulocyte count	26	150	0.173333333333333
P wave duration	4	23	0.173913043478261
Fasting blood insulin (BMI interaction)	4	20	0.2
Cognitive decline rate in late mild cognitive impairment	12	143	0.0839160839160839
Lapatinib-induced hepatotoxicity	1	1	1
Hypertension (young onset)	1	4	0.25
Immunoglobulin light chain (AL) amyloidosis	3	10	0.3
Cognitive performance	22	121	0.181818181818182
White matter hyperintensity burden	6	38	0.157894736842105
Breast cancer (estrogen-receptor negative, progesterone-receptor negative, and human epidermal growth factor-receptor negative)	2	5	0.4
Severe malaria	1	18	0.0555555555555556
Alcohol consumption in current drinkers	1	8	0.125
Renal underexcretion gout	1	8	0.125
Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine)	3	5	0.6
Immunoglobulin light chain (AL) amyloidosis (serum Ig light chain only lambda/kappa based profile)	1	1	1
Hypertension	4	55	0.0727272727272727
Resting metabolic rate	3	10	0.3
Coagulation factor levels	4	14	0.285714285714286
Ewing sarcoma	1	3	0.333333333333333
Psychotic symptoms in prion disease	1	3	0.333333333333333
Adolescent idiopathic scoliosis	7	18	0.388888888888889
Asthma or chronic obstructive pulmonary disease	1	3	0.333333333333333
Adverse response to chemotherapy in breast cancer (alopecia) (docetaxel)	1	4	0.25
RR interval (heart rate)	4	20	0.2
White matter integrity	1	9	0.111111111111111
Open-angle glaucoma and vertical cup-disc ratio	1	2	0.5
Superior frontal gyrus grey matter volume	2	11	0.181818181818182
Alcohol consumption (drinkers vs non-drinkers)	1	7	0.142857142857143
Fasting blood glucose (BMI interaction)	7	33	0.212121212121212
Monobrow	6	49	0.122448979591837
Palmitoleic acid (16:1n-7) levels	6	19	0.315789473684211
PR interval	8	45	0.177777777777778
Basal cell carcinoma	11	66	0.166666666666667
Waist-to-hip ratio adjusted for BMI in inactive individuals	5	8	0.625
Ankylosing spondylitis	33	95	0.347368421052632
Alzheimer's disease in APOE e4- carriers	6	32	0.1875
Primary vesicoureteric reflux	1	1	1
Ankylosing spondylitis (SNP x SNP interaction)	1	4	0.25
Cutaneous lupus erythematosus	1	7	0.142857142857143
Intrinsic epigenetic age acceleration	1	6	0.166666666666667
Periodontitis (Mean PAL)	5	37	0.135135135135135
Cerebrospinal fluid t-tau:AB1-42 ratio	4	30	0.133333333333333
Common traits (Other)	5	16	0.3125
Systolic blood pressure (alcohol consumption interaction)	2	11	0.181818181818182
Corrected insulin response	2	6	0.333333333333333
C-reactive protein levels or total cholesterol levels (pleiotropy)	6	20	0.3
Cerebrospinal fluid levels of Alzheimer's disease-related proteins	1	5	0.2
Non-small cell lung cancer	5	17	0.294117647058824
Airway imaging phenotypes	1	14	0.0714285714285714
Oral cavity and pharyngeal cancer	2	10	0.2
Echocardiographic traits	2	8	0.25
Venlafaxine response in generalised anxiety disorder (remitters vs non-remitters after 12 weeks)	1	4	0.25
Menarche (age at onset)	38	235	0.161702127659574
Metabolite levels (HVA/MHPG ratio)	3	25	0.12
Hepatocyte growth factor levels	3	25	0.12
Susceptibility to persistent hepatitis B virus infection	1	4	0.25
Femoral neck bone geometry and menarche (age at onset)	2	6	0.333333333333333
DNA methylation (variation)	3	19	0.157894736842105
Eating disorders	2	15	0.133333333333333
HIV-1 viral setpoint	8	33	0.242424242424242
Proinsulin levels	2	10	0.2
Tourette syndrome	1	7	0.142857142857143
Response to paliperidone in schizophrenia (negative Marder score)	2	64	0.03125
Facial morphology (factor 9, facial height related to vertical position of nasion)	1	18	0.0555555555555556
Hirschsprung disease	5	22	0.227272727272727
Percent mammographic density	1	7	0.142857142857143
Tuberculosis	17	109	0.155963302752294
Lipoprotein(a) levels adjusted for apolipoprotein(a) isoforms	1	28	0.0357142857142857
Eye color traits	1	3	0.333333333333333
Serum magnesium levels	1	1	1
Optic disc parameters	1	3	0.333333333333333
Conduct disorder (symptom count)	5	17	0.294117647058824
Bone mineral density (paediatric, upper limb)	2	11	0.181818181818182
Obsessive-compulsive symptoms	3	13	0.230769230769231
Thyroid volume	3	8	0.375
Birth length	2	6	0.333333333333333
Hepatitis B (viral clearance)	4	4	1
Opioid dependence	1	12	0.0833333333333333
Temperament	5	16	0.3125
Bone mineral density (hip) and age at menarche	1	8	0.125
Post-traumatic stress disorder	5	26	0.192307692307692
Economic and political preferences (environmentalism)	2	17	0.117647058823529
Heart failure	1	17	0.0588235294117647
Prostate cancer (early onset)	2	9	0.222222222222222
Creutzfeldt-Jakob disease (variant)	1	6	0.166666666666667
Leprosy	7	40	0.175
Autism spectrum disorder	3	8	0.375
Aging (facial)	1	7	0.142857142857143
Mammographic density (non-dense area)	1	8	0.125
Pharmacokinetics of olanzapine in severe mental disorder (concentration dose ratio)	2	4	0.5
Anthracycline-induced cardiotoxicity in childhood cancer	2	2	1
Non-response to antidepressants and depression	1	5	0.2
Serum galactose-deficient IgA1 levels	1	4	0.25
Red blood cell fatty acid levels	1	13	0.0769230769230769
Appendicular lean mass	1	5	0.2
Myocardial infarction	16	53	0.30188679245283
Non-alcoholic fatty liver disease histology (other)	6	20	0.3
Bronchodilator response in asthma	1	1	1
Urinary albumin-to-creatinine ratio in diabetes	1	2	0.5
Depressive symptoms (SSRI exposure interaction)	3	10	0.3
Osteoarthritis (hip)	1	5	0.2
High-grade serous ovarian cancer	4	19	0.210526315789474
Serum protein levels (sST2)	3	14	0.214285714285714
Pancreatitis	1	5	0.2
Itch intensity from mosquito bite adjusted by bite size	34	336	0.101190476190476
Triglyceride to HDL cholesterol ratio	1	2	0.5
Diisocyanate-induced asthma	36	180	0.2
C-reactive protein levels or HDL-cholesterol levels (pleiotropy)	2	20	0.1
Acne (severe)	4	17	0.235294117647059
Lymphocyte counts	38	182	0.208791208791209
Moderate or severe diarrhoea in darapladib-treated cardiovascular disease (time to event)	2	7	0.285714285714286
Yeast infection	1	48	0.0208333333333333
Progression free survival in metastatic colorectal cancer (CAPOX-B vs CAPOX-B plus cetuximab)	2	3	0.666666666666667
Food allergy (maternal genetic effects)	1	5	0.2
Neutrophil count	32	179	0.17877094972067
Sex hormone levels	3	15	0.2
Facial morphology (factor 8, orbital inclination due to vertical and horizontal position of exocanthion)	3	18	0.166666666666667
Immune reponse to smallpox (secreted IFN-alpha)	7	32	0.21875
Malaria	1	13	0.0769230769230769
Asthma (childhood onset)	11	66	0.166666666666667
Bone ultrasound measurement (velocity of sound)	3	21	0.142857142857143
Glomerular filtration rate in chronic kidney disease	1	22	0.0454545454545455
Hematological parameters	3	12	0.25
Parkinson's disease	38	212	0.179245283018868
Smoking cessation	2	5	0.4
Keloid	1	4	0.25
Cerebrospinal P-tau181p levels	8	31	0.258064516129032
White matter lesion progression (adjusted for white matter lesion burden at baseline)	1	6	0.166666666666667
Immune response to smallpox vaccine (IL-6)	14	46	0.304347826086957
HDL Cholesterol - Triglycerides (HDLC-TG)	1	8	0.125
Heroin dependence	2	5	0.4
Papillary thyroid cancer	1	9	0.111111111111111
Common carotid intima-media thickness	2	10	0.2
Serum total protein level	2	12	0.166666666666667
Allergic rhinitis	12	35	0.342857142857143
Monocyte chemoattractant protein-1 levels	3	56	0.0535714285714286
Lipid traits	5	31	0.161290322580645
Chronic sinus infection	1	45	0.0222222222222222
Age-related hearing impairment	6	32	0.1875
Peripheral arterial disease (traffic-related air pollution interaction)	33	159	0.207547169811321
Permanent tooth development	2	4	0.5
Diastolic blood pressure (alcohol consumption interaction)	3	4	0.75
Systemic sclerosis (anti-topoisomerase-positive)	3	6	0.5
Glomerular filtration rate in non diabetics (creatinine)	7	37	0.189189189189189
Post bronchodilator FEV1/FVC ratio	137	1631	0.0839975475168608
Glomerular filtration rate	16	52	0.307692307692308
Multiple myeloma (hyperdiploidy)	1	14	0.0714285714285714
Biochemical measures	7	17	0.411764705882353
Multiple keratinocyte cancers	1	11	0.0909090909090909
Adiponectin levels (BMI-adjusted)	1	4	0.25
Gestational age at birth (maternal effect)	4	16	0.25
Glioma	13	47	0.276595744680851
Alcohol dependence (age at onset)	2	26	0.0769230769230769
Platelet distribution width	37	200	0.185
Gestational age at birth in premature rupture of membrane-initiated deliveries (child effect)	2	8	0.25
Asthma (sex interaction)	2	6	0.333333333333333
Emphysema distribution in smoking	1	9	0.111111111111111
C-reactive protein	7	38	0.184210526315789
Blood pressure measurement (low sodium intervention)	4	10	0.4
Heschl's gyrus morphology	7	33	0.212121212121212
Brain structure	2	21	0.0952380952380952
Noise-induced hearing loss	1	1	1
Hemostatic factors and hematological phenotypes	7	30	0.233333333333333
Ischemic stroke (large artery atherosclerosis)	1	5	0.2
Migraine - clinic-based	8	37	0.216216216216216
Egg allergy (parent-of-origin effect)	1	3	0.333333333333333
Attention deficit hyperactivity disorder (combined symptoms)	8	21	0.380952380952381
Stem cell factor levels	2	29	0.0689655172413793
IgE levels in asthmatics (D.p. specific)	1	3	0.333333333333333
Homocysteine levels	2	21	0.0952380952380952
Body mass index (change over time)	2	10	0.2
Cough in response to angiotensin-converting enzyme inhibitor drugs	1	33	0.0303030303030303
Objective response to lithium treatment in bipolar disorder	1	4	0.25
Suicide attempts in bipolar disorder	2	3	0.666666666666667
Estrogen receptor status in breast cancer	1	1	1
Neutralising antibody response to interferon beta therapy in multiple sclerosis (presence of antibodies)	1	1	1
Accelerated cognitive decline after conversion of mild cognitive impairment to Alzheimer's disease (Alzhiemer's diagnosis trajectory interaction)	2	11	0.181818181818182
Multiple system atrophy	4	22	0.181818181818182
Colorectal cancer (diet interaction)	2	13	0.153846153846154
Puberty onset (genital enlargement)	1	1	1
Heart rate variability traits (RMSSD)	3	24	0.125
Mixed cryoglobulinemia vasculitis in chronic hepatitis C infection	1	2	0.5
Asthma and hay fever	3	21	0.142857142857143
Response to mTOR inhibitor (rapamycin)	2	5	0.4
Pharmacokinetics of antiepileptic drugs in severe mental disorder (concentration drug ratio)	1	4	0.25
Urate levels (BMI interaction)	2	22	0.0909090909090909
Allergic sensitization	3	12	0.25
Colorectal cancer (oestrogen-progestogen hormone therapy interaction)	1	1	1
Oleic acid (18:1n-9) levels	5	13	0.384615384615385
Blood pressure measurement (high sodium and potassium intervention)	7	13	0.538461538461538
CTACK levels	2	46	0.0434782608695652
Diastolic blood pressure	37	268	0.138059701492537
Hemoglobin levels	6	22	0.272727272727273
Myeloid white cell count	28	159	0.176100628930818
Cervical artery dissection	2	5	0.4
C-reactive protein levels	8	26	0.307692307692308
Glaucoma (primary open-angle)	8	38	0.210526315789474
Personality dimensions	7	22	0.318181818181818
Cingulate cortical amyloid beta load	2	5	0.4
Subclinical atherosclerosis traits (other)	1	8	0.125
Vascular dementia	1	1	1
Lipoprotein phospholipase A2 activity in cardiovascular disease	1	16	0.0625
Subcutaneous adipose tissue	11	56	0.196428571428571
Number of common colds	2	34	0.0588235294117647
LDL cholesterol levels	22	84	0.261904761904762
Serum thyroid-stimulating hormone levels	4	22	0.181818181818182
Bipolar disorder (body mass index interaction)	6	51	0.117647058823529
Colorectal adenoma (advanced)	11	29	0.379310344827586
Breast cancer in childhood cancer survivors treated with less than 10 gray radiotherapy	2	3	0.666666666666667
Post bronchodilator FEV1	133	1182	0.112521150592217
Lung function (FEV1/FVC) in asthma (dust mite allergen exposure interaction)	1	2	0.5
Disease progression in age-related macular degeneration	5	61	0.0819672131147541
Obsessive-compulsive disorder or autism spectrum disorder	2	13	0.153846153846154
Response to cytidine analogues (gemcitabine)	4	10	0.4
Bronchopulmonary dysplasia	4	26	0.153846153846154
Squamous cell lung carcinoma	7	101	0.0693069306930693
Parental longevity (mother's age at death)	4	47	0.0851063829787234
Glycemic traits (pregnancy)	5	10	0.5
Alcohol consumption (transferrin glycosylation)	3	6	0.5
Late-onset myasthenia gravis	3	11	0.272727272727273
Plasma thyroid-stimulating hormone levels	1	10	0.1
Depression in response to interferon-based therapy in chronic hepatitis C	1	4	0.25
Bilirubin levels	17	50	0.34
Ovarian cancer in BRCA2 mutation carriers	1	2	0.5
Pediatric bone mineral density (spine)	2	15	0.133333333333333
Hemoglobin	2	13	0.153846153846154
Total body bone mineral density	29	236	0.122881355932203
Prevalent atrial fibrillation	1	9	0.111111111111111
Systolic blood pressure	49	232	0.211206896551724
Response to radiotherapy in prostate cancer (toxicity, decreased urine stream)	1	8	0.125
GIP levels in response to oral glucose tolerance test (fasting)	1	2	0.5
Pediatric bone mineral content (hip)	1	15	0.0666666666666667
Motion sickness	3	35	0.0857142857142857
Chronic hepatitis C infection	1	7	0.142857142857143
Iron status biomarkers (transferrin levels)	2	9	0.222222222222222
Chronic kidney disease and serum creatinine levels	1	4	0.25
Educational attainment	18	95	0.189473684210526
Pulmonary function	14	67	0.208955223880597
Gestational age at birth in premature rupture of membrane-initiated deliveries (maternal effect)	1	8	0.125
Esophageal cancer (squamous cell)	2	7	0.285714285714286
Prostate-specific antigen levels (conditioned on lead SNPs)	3	21	0.142857142857143
Emphysema-related traits	2	7	0.285714285714286
Food antigen IgG levels	2	7	0.285714285714286
Gondoic acid (20:1n-9) levels	1	4	0.25
Initial pursuit acceleration	8	47	0.170212765957447
Chin dimples	3	46	0.0652173913043478
Elevated serum carcinoembryonic antigen levels	3	13	0.230769230769231
Cardiovascular disease in hypertension (calcium channel blocker interaction)	1	2	0.5
Coronary atherosclerosis (increased number of diseased vessels) (traffic exposure interaction)	2	15	0.133333333333333
Amyotrophic lateral sclerosis	15	92	0.16304347826087
Large B-cell lymphoma	1	2	0.5
Aging	3	9	0.333333333333333
Emphysema imaging phenotypes	7	52	0.134615384615385
Age-related macular degeneration (wet)	1	1	1
Primary tooth development (time to first tooth eruption)	3	19	0.157894736842105
Response to efavirenz-containing treatment in HIV 1 infection (virologic failure)	3	35	0.0857142857142857
Angiotensin-converting enzyme activity	1	2	0.5
Multiple cancers (lung cancer, gastric cancer, and squamous cell carcinoma)	4	7	0.571428571428571
